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ABSTRACT 
 
Salmonella infections remain one of the most common food borne diseases worldwide. 
Gastroenteritis, which can be caused by many non-typhoidal Salmonella (NTS) serovars, is 
relatively common in North America. One of the main risk factors of NTS gastroenteritis is 
travel to endemic areas in the developing world. The current treatment of NTS infections with 
antibiotics is reserved for severe cases. A growing concern with antibiotic use is that clinical 
isolates are becoming drug resistant. Although most NTS infections are self-limiting in nature, 
the burden on the body and recovery can take several months. Thus, it is vital to prevent NTS 
infections rather than solely rely on treatment. 
We have previously discovered two novel surface associated polysaccharides in 
Salmonella: O-Antigen capsule and X-factor. Not only O-Antigen Capsule is considered a 
common surface antigen, but its’ genes were found to be expressed during in vivo infections in 
mice. Such an antigen would be a suitable candidate in developing a vaccine against Salmonella 
induced gastroenteritis. The goal of this research was to evaluate the use of O-Antigen capsule to 
develop a traveler’s vaccine for NTS associated gastroenteritis.  
Results and Conclusions: We have developed a purification protocol and purified the 
capsule and X-factor from Salmonella Typhimurium, Enteritidis, and Heidelberg. 
Lipopolysaccharide (LPS) was co-isolated with O-Antigen capsule, but removed using Triton 
extraction. Salmonella LPS is strain-specific and an adaptive immune response against LPS will 
not provide cross-protection. We generated specific immune sera in rabbits to recognize O-
Antigen capsule and X-factor produced by Salmonella Typhimurium and Enteritidis. We used a 
mouse model to determine the immunization dose of O-Antigen capsule and showed that 
conjugation is necessary to enhance the immune response in mice. 
To boost capsule production, we analyzed PyihUTSRQPO activity using a luciferase-based 
reporter system. Deletion of a putative transcriptional repressor (YihW) resulted in over 100-fold 
increase in PyihUTSRQPO confirming YihW as a repressor. We have also looked at the effect of 
growth media, temperature, and sugar precursors on PyihUTSRQPO activity, and were able to 
show that PyihUTSRQPO has highest activity in Tryptone broth at 30oC in the absence of any 
additional sugars.  
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1.0 LITERATURE REVIEW 
 
1.1 Introduction to Salmonella  
1.1.1 Nomenclature and Classification  
 
Salmonella are a diverse group of bacteria that belong to the same family as Escherichia 
and Shigella. Salmonella consist of two species known as bongori and enterica (Figure 1.1.1). S. 
bongori mainly infect cold blooded animals, but can cause rare infections in humans (Fookes et 
al., 2011). S. enterica are Gram-negative, facultative anaerobic bacteria that can invade a wide 
range of warm blooded animals causing acute and chronic infections. According to the White-
Kauffmann-Le Minor scheme S. enteria is further divided in to six subspecies: enterica, 
salamae, arizonae, diarizonae, houtenae, and indica. S. enterica subspecies enterica is the group 
responsible for the majority of the human infections. Subspecies enterica isolates can be 
categorized into two main groups referred to as Typhoidal and Non-Typhoidal Salmonella (NTS) 
(Hurley et al., 2014). Typhoidal Salmonella, Salmonella ser. Typhi and Salmonella ser. 
Paratyphi, tend to be human restricted, while Non-Typhoidal Salmonella (NTS) infect a broad 
range of hosts including; humans, chickens, reptiles, birds, amphibians, pigs, cows, and horses 
(Hurley et al., 2014).  
Classification of Salmonella is based on serology to three main surface antigens: O, H, and 
K antigens. The O antigen refers to oligosaccharides that are part of lipopolysaccharide (LPS) on 
the outer membrane, the H antigen refers to flagella proteins, and the K antigen refers to capsular 
polysaccharides. For example, the Vi antigen, being a subtype of capsule’s K antigen, is only 
expressed by S. Typhi (McQuiston et al., 2011; Grimont and Weill, 2007). Each unique 
combination of O, H and K antigens lead to the designation of a new serovar (Grimont and 
Weill, 2007). 
Classification of serovars has evolved over time, where serovar names can indicate the 
syndrome (Salmonella ser. Typhi), relationship (Salmonella ser. Paratyphi A, B, and C), 
syndrome and host specificity (Salmonella ser. Abortusequi), or geographical origin (Salmonella 
ser. London). With time, names were maintained only for serovars from subspecies enterica, 
while serovars of other S. enterica subspecies and S. bongori are designated only by their 
antigenic formula. Salmonella enterica, subspecies enterica serovar Typhimurium in abbreviated 
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form is referred to as Salmonella ser. Typhimurium, or S. enterica serovar Typhimurium 
(Grimont and Weill, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.1: Phylogenetic tree and White-Kauffmann-Le Minor classification of Salmonella. Salmonella are 
divided in to two species, S. enterica and S. bongori. S. enterica is further divided in to six sub-species: enterica, 
salamae, arizonae, diarizonae, houtenae, and indica. Serovars of S. enterica subspecies enterica falls in to two main 
categories called Typhoidal and Non-Typhoidal Salmonella (NTS). Below each name is a numerical value 
corresponding to the current number of serovars in the given category. Figure adopted with modifications from 
Grimont and Weill, 2007. 
 
S. enterica subspecies enterica serovars can also be grouped as host generalist, host 
adapted, or host restricted. Host generalist serovars like Salmonella ser. Typhimurium and 
Salmonella ser. Enteritidis have the ability to infect multiple species. Host adapted serovars like 
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Salmonella ser.  Choleraesuis (in swine), and Salmonella ser. Dublin (in cattle), usually cause 
disease in one species, but is capable of causing disease in other species as well. Host restricted 
serovars like Salmonella ser. Typhi, Salmonella ser. Paratyphi (human), and Salmonella ser. 
Gallinarum (poultry) cause disease in only one species and are usually characterize by the loss of 
function of certain virulence genes (Uzzau et al., 2000; Waldner et al., 2012). 
 
1.1.2 Disease and Importance  
 
Salmonellosis is the intestinal illness that arises after ingestion of Salmonella contaminated 
food or water  and  is one of the most common, yet preventable, food borne diseases present 
throughout the world (Hurley et al., 2014). The two most common Salmonella serovars in North 
America are Salmonella ser. Typhimurium and Salmonella ser. Enteritidis (Public Health 
Agency of Canada 2007). Each year the reported number of Salmonella infections range from 
6,000-12,000 cases in Canada. However, this number does not reflect the milder, undiagnosed 
cases that are mostly mistaken for Stomach flu (Canadian Meat Council 2015). Among Canadian 
travellers, travel to Asia and Caribbean were the most common destinations associated with 
travel acquired NTS infections (Public Health Agency of Canada 2014). In the four largest 
provinces of Canada (Ontario, Quebec, British Columbia, and Alberta) Salmonella ser. 
Typhimurium and Salmonella ser. Enteritidis isolates are mainly recovered from individuals over 
50 years of age. Although Salmonella ser. Heidelberg isolates are recovered from all age groups, 
in one population study more than 200 isolates of Salmonella ser. Heidelberg were recovered 
from blood of individuals over 50 years of age (Figure 1.1.2) (Public Health Agency of Canada 
2007).  
After eight years, 2012 marked the change in ranking of the three most common 
Salmonella serovars in Canada from Salmonella ser. Typhimurium, Enteritidis, and Heidelberg, 
to Salmonella ser. Typhimurium, Heidelberg, and Enteritidis respectively (Public Health Agency 
of Canada 2014). This is not surprising considering the large number of ceftiofur (a third 
generation cephalosporin used in animals) resistant Salmonella ser. Heidelberg isolates found in 
Canadian poultry. Of more significance is that ceftiofur resistance is correlated with ceftriaxone, 
cefoxitin, amoxicillin-clavulanic acid, and ampicillin (antibiotics used in humans) resistance. As 
extra-intestinal Salmonellosis in young children and pregnant women are treated with 
 4 
Ceftriaxone, it is recognized as a drug of very high importance to human medicine. Thus, 
patients infected with even moderately Ceftriaxone resistant Salmonella ser. Heidelberg are at 
elevated risk of ceftriaxone therapy failure (Public Health Agency of Canada 2007). 
 
Figure 1.1.2: Salmonella isolates recovered from patients’ blood samples in Canada; according to the age 
category.  Samples were collected during the first half of each month from 2003-2005 in the largest four provinces: 
British Columbia, Alberta, Ontario, and Quebec. Figure extracted from Public Health Agency of Canada 2007, 
reproduced with kind permission from the Public Health Agency of Canada. 
 
In the United States Salmonella causes 1.4 million infections and 600 deaths annually 
(Public Health Agency of Canada 2011). According to the foodborne Diseases Active 
Surveillance Network, Salmonella infections are the leading cause of hospitalizations and death 
among foodborne pathogens (Centers for Diseases Control and Prevention 2011). In the United 
States, the economic cost of Salmonella infections in terms of lost productivity and medical 
expenses have been estimated to be in the billions of dollars (Voetsch et al., 2004).  Annually 
NTS cause over 94 million infections and 155 000 deaths worldwide (Majowicz et al., 2010). In 
developing countries the mortality rate can reach up to 24%, with certain serotypes having higher 
mortality rates than others. Salmonella are also responsible for 20% of childhood diarrhoea and 
mortality in developing countries (Public Health Agency of Canada 2011). However, 60-80% of 
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Salmonellosis cases are thought to be either not diagnosed at all or are classified as sporadic 
cases (World Health Organization 2014).  
The number of NTS infections has risen throughout the world in correlation with increased 
incidences of HIV and malaria, which predispose patients for Salmonella infection. In Sub-
Saharan Africa, a place notorious for enteric fever, NTS infections are becoming the cause of as 
many as 50% of diagnosed bacteremia cases (Andrews-Polymenis, et al., 2010). Genomic 
sequencing has identified that NTS is the primary cause of bacteremia in Malawi children, with 
up to 75% of these infections being caused by Salmonella ser. Typhimurium (Andrews-
Polymenis, et al., 2010).  
Although most serotypes of Salmonella can cause disease in humans, as discussed above, 
some are host-adopted. When animal host adopted species cause disease in humans, it can be 
quite severe and even deadly. The host range of individual isolates is affected by genome 
degradation, differential transcriptional regulation, and prophage repertoire (Kingsley et al., 
2009). Salmonella ser. Enteritidis and Salmonella ser. Typhimurium are the most commonly 
transmitted serovars from animals to humans (Wold Health Organization 2013). There are a wide 
range of species acting as reservoirs of Salmonella, including livestock and poultry (Alberta 
Health and Wellness 2011).  
NTS can survive for many weeks, even up to years in non-host environments. For example, 
Salmonella can survive up to 63 days in frozen yogurt (el-Gazzar and Marth 1992). Salmonella 
ser. Choleraesuis can survive in dry swine feces for up to 13 months (Gray and Fedorka-Cray 
2001), Salmonella ser. Dublin can survive in feces spread on rubber, polyester, and concrete for 
up to 6 years, Salmonella ser. Typhimurium can survive in water for up to 152 days, and soil for 
231 days (Public Health Agency of Canada 2011). Surprisingly, Salmonella can also survive on 
low moisture products, such as spray dried milk, nuts, cereal, and dry seasonings, for extended 
periods of time (Podolak et al., 2010; Waldner et al., 2012). 
NTS are capable of causing gastroenteritis and bacteremia. Symptoms of gastroenteritis, 
such as abdominal cramps, diarrhea, nausea, vomiting, chills, fever, and headache, typically 
develop 6-72 hours after ingestion of Salmonella species. These symptoms can last up to 2-7 
days depending on the initial concentration of bacteria ingested, serotype, age and the immune 
status of the host among many other factors (World Health Organization 2014; Public Health 
Agency of Canada 2011). Although most infected individuals recover without treatment within 
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few days, clinical manifestation depends on the susceptibility (i.e., immune status) of the host 
(De Jong et al., 2012). NTS infections are most commonly associated with gastroenteritis. Even 
though most infections are self-limiting, in rare cases (3-10%) they can lead to bacteremia. The 
risk of bacteremia is higher in immunosuppressed individuals, infants, and the elderly. 
Bacteremia can lead to further complications, such as  endocarditis, septic shock, infection of 
liver, spleen, biliary tract, aorta, and urinary tract, mesenteric lymphadenitis, pneumonia, 
osteomyelitis, pulmonary and brain abscess, empyema, meningitis, CNS infections and death 
(Public Health Agency of Canada 2011). In addition, perforation of the gut and necrosis of 
Peyer’s patches can result in toxic encephalopathy (De Jong et al., 2012). 
Human transmission occurs through ingestion of Salmonella contaminated food or water 
and contact with infected animals, especially food animals and pets, and animal feed. In addition, 
Salmonella can be acquired through ingestion of raw or undercooked poultry and meat among 
many other food sources. Person to person transmission through fecal oral route is also possible 
and is further facilitated by inadequate hand washing. Water and food sources soiled with urinary 
or fecal matter from humans and animals shedding Salmonella act as reservoirs and allow easy 
transmission (Public Health Agency of Canada 2011).  
Preliminary diagnosis is mainly based on symptoms and travel history, and can be 
confirmed by serotyping specimen from stool, rectal swabs, vomit, urine, deep tissue wound, or 
sterile site at the public health lab (Public Health Agency of Canada 2011; Alberta Health and 
Wellness 2011). As this process can take over two weeks, treatment options are made available 
to the patient prior to disease confirmation (Centers for Diseases Control and Prevention 2010). 
Treatment is usually based on the symptoms and will include electrolyte replacement (lost 
through diarrhea and vomiting) and rehydration (World Health Organization 2014). 
Antimicrobial therapy is usually reserved for immunocompromised patients, infants, children, 
the elderly and for severe cases of gastroenteritis; as unnecessary administration of antibiotics 
can select for resistant strains (World Health Organization 2014). Commonly used antibiotics 
include ciproflaxin, cephalosporins, ampicillin, and Trimethoprim/Sulfamethoxazole (Public 
Health Agency of Canada 2011). 
Multidrug resistant Salmonella strains have emerged as far back as 1989 (Public Health 
Agency of Canada 2011). As of 1997, more than 70% of clinical isolates showed resistance to 
ampicillin, tetracycline, sulphonamides, streptomycin, and chloramphenicol. A few strains were 
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even resistant to nalidixic acid, trimethoprim, sulfamethoxazole, and kanamycin (Brisabois et al., 
1997). Although vaccines are available for typhoid fever, currently there are no vaccines 
available for NTS infections.  
Preventive measures should be exercised throughout the food chain from production, 
processing and manufacturing to food preparation at home and in commercial settings. Animal 
contact should happen with care and infants should be monitored around pet animals. Consuming 
properly cooked food, especially meat, poultry, and egg; drinking boiled water and pasteurized 
milk and juices; washing fruits and vegetables eaten raw; and proper hand washing can decrease 
the incidents of Salmonellosis (World Health Organization 2014). Proper sanitation, access to 
clean water supplies and treatment of infected individuals are among the best prophylactic 
measures to prevent the spread of Salmonellosis in endemic regions (Public Health Agency of 
Canada 2011).  
Global surveillance of Salmonellosis is mainly conducted by the Centers for Disease 
Control and Prevention (CDC) and World Health Organization (WHO). In Canada, there’s a 
hierarchical surveillance system starting from local hospitals to provincial and national health 
authorities. More specifically, the National Notifiable Disease Summary Program (NDRS), 
National Enteric Surveillance Program (NESP) and the federal government of Canada. These 
organizations maintain demographic and epidemiological data related to Salmonella outbreaks in 
Canada (Public Health Agency of Canada 2009). Salmonellosis was the most common pathogen 
reported to the Canadian National Enteric Surveillance Program (NESP) in 2012 with 220 
different serovars and 6979 isolates. From these, Salmonella ser. Enteritidis consisted of 30% of 
recovered isolates (Public Health Agency of Canada 2009).  
 
1.1.3 Clinical Manifestation  
 
Within the host’s stomach, Salmonella are exposed to a range of stress conditions 
including low pH, heat shock, and oxidative stress. Salmonella that survive these conditions 
travel to the small intestine and compete with host normal flora for space and nutrients 
(Chaudhuri et al., 2013; Jones 1997). In addition, Salmonella also have to evade killing by bile 
salts, digestive enzymes, antimicrobial peptides, and secretory IgA prior to attaching intestinal 
epithelial cells through fimbriae (Haraga et al., 2008).  
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Salmonella pathogenesis begins when cells cross the intestinal epithelial barrier and enters 
mesenteric lymph nodes either through active invasion, especially of microfold (M) cells, 
bacterial mediated endocytosis by non-phagocytic enterocytes, or passive transport through 
dendritic cells that extend pseudopods through tight junctions into the basolateral side of the 
intestinal barrier (Jones et al., 1994; Haraga et al., 2008). Bacteria mediated endocytosis lead to 
intestinal inflammation and diarrhoea (Haraga et al., 2008). A hallmark of Salmonellosis is the 
massive inflammatory response elicited by the host innate immune system in response to the 
pathogen associated and secreted effector molecules (Hurley et al., 2014). Salmonella use 
multiple effectors to downregulate the host immune response, thereby facilitating intestinal 
colonization over long periods of time (Haraga et al., 2008).  
Two main categories of proinflammatory stimuli are observed during Salmonella 
infections. These are (a) virulence-associated factors that abuse host processes and cell 
machinery, ultimately resulting in disease pathology, and (b) pathogen-associated factors 
stimulating the host innate immune system (Hurley et al., 2014). In Salmonella colonization and 
survival within host cells are mainly regulated by Salmonella pathogenicity islands (SPI): 
clusters of genes acquired through horizontal gene transfer (Ibarra and Steele-Mortimer, 2009). 
SPI-1 and SPI-2 are very important in in vivo infections as Type III secretion systems (T3SSs) 
encoded by these SPIs are used to secrete effector proteins into the host cell cytoplasm (Galan, 
1999).   
Mechanisms employed by Salmonella: NTS can invade both phagocytic (dendritic cells 
and macrophages) and non-phagocytic cells (intestinal epithelial cells) (Portillo and Finlay 
1994). During entry Salmonella induce the formation of membrane ruffles (protrusions) at the 
site of attachment (Jones 1997). Actin filament rearrangements enclose and internalize 
Salmonella containing membrane ruffles (Coombes et al., 2005). Internalization of Salmonella is 
mediated by SPI-1 T3SS effector proteins SopE, SopE2, and SopB. These effector proteins can 
activate host Rho GTPases Cdc42, Rac1 and RhoG leading to cytoskeletal reorganization, 
formation of membrane ruffles, and internalization of Salmonella through micropinocytosis 
(Haraga et al., 2008). In addition, these effector molecules stimulate transcriptional re-
programming in host cells through STAT3 activation. Salmonella-induced gene expression 
changes include signal transduction, membrane trafficking, cytoskeletal architecture, and 
production of pro-inflammatory cytokines to facilitate survival of Salmonella within host cells 
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(Galan, 1999; Haraga et al., 2008; Hannemann et al., 2013). For example it has been 
demonstrated that mature dendritic cells produce CCL19, an important chemoatract regulating 
dendritic cell migration, which binds to CC chemokine receptor 7 on naïve T cells and mature 
dendritic cells. Mature murine dendritic cells containing Salmonella were chemoattracted toward 
CCL19 produced and secreted in secondary lymphoid organs. Therefore it was proposed that 
CCL19 secretion by dendritic cells may have a role in dissemination of Salmonella throughout 
the body (Pietila et al., 2005, and Cheminay et al., 2002). Recent evidence suggest that the 
metabolic pathway utilized by Salmonella are specifically adapted to take advantage of the 
inflamed intestinal environment and outcompete the normal flora that are present (Nuccio and 
Baumler 2014). 
In addition, Salmonella remodel surface molecules to evade immune recognition. These 
include repression of flagella and SPI1 T3SS expression, decrease length of O-Antigen of LPS, 
alterations to the acyl chain in the lipid-A component, protein content changes in the outer and 
inner membranes and peptidoglycan layer (Haraga et al., 2008). Effector proteins secreted by 
SPI-1 T3SS, especially SipA, facilitate bacterial uptake and induce inflammation and recruit 
polymorphonuclear (PMN) cells across the intestinal epithelium (Haraga et al., 2008). SipA, IL-8 
and pathogen-elicited epithelial chemoattractants (PEEC) in turn recruit neutrophils to the site of 
infection (McCormick et al., 1993). As discussed above, migration of neutrophils to the intestine 
leads to a massive inflammation, clinically described as acute infection (Bellet et al., 2013). 
Signaling by SPI-1 released effector proteins also lead to NF-κB signaling and activation of 
caspase-1, which activate IL-1β, IL-18 and SipB. SipB is a powerful mediator of inflammation 
and pyroptotic cell death (Hurley et al., 2014). Salmonella ser. Typhimurium is also able to 
induce cell death through caspase-1 and NLRC4 activation, where NLRC4 can recognize 
accidental injection of flagella by T3SS in to the host cell cytosol (De Jong et al., 2012). 
Within macrophages Salmonella reside in membrane-bound compartments known as 
Salmonella containing vacuoles (SCV). Within SCV, SPI-2 T3SS-secreted effector proteins 
delay the endosomal fusion with lysosome and thereby evade the immune recognition (Coombes 
et al., 2005). In addition, SPI-2 effector proteins are involved in enterocolitis and have a role in 
pro-inflammatory activity and intracellular persistence.  
Mechanisms employed by the host: Host cells recognize Salmonella through pathogen 
associated molecular patterns (PAMP); such as LPS, flagella, peptidoglycan, doublestranded 
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RNA, and unmethylated CpG motifs, and host derived damage associated molecular patterns 
(DAMP) such as extracellular matrix (ECM) compounds, secreted immunomodulatory proteins, 
and stress induced molecules (Tolle and Standiford, 2013; Kawai and Akira, 2010). When 
PAMPs and DAMPs interact with pattern recognition receptors (PRR) such as Toll-like receptors 
(TLRs), and NOD-like receptors (NLRs) on host cell surfaces, a signaling cascade is activated to 
recruit phagocytic cells such as neutrophils and dendritic cells to the site of infection (Hurley et 
al., 2014). In turn these phagocytic cells secrete pro-inflammatory cytokines IL-6, IL-1β, TNF-α 
and INF-γ and establish a network between innate and adaptive immune systems. INF-γ is 
involved in extending macrophage activation and increasing phagosome-lysosome fusion while 
IL-18 is important for early innate resistant to Salmonella (De Jong et al., 2012; Jones 1997). 
This was shown where mice deficient in caspase-1, IL-1β, or IL-18 had higher titers of bacteria 
and were readily susceptible for Salmonella ser. Typhimurium infection (Raupach et al., 2006). 
Although both neutrophils and macrophages phagocytose and destroy Salmonella, macrophages 
are capable of killing both self-targeted Salmonella and other infected host cells (Delves et al., 
2011).  
Macrophages target Salmonella both through oxygen-dependent and independent 
mechanisms. Primary oxygen-dependent killing involve secretion of hydrogen peroxide, 
superoxide, and hydroxyl radicals in to SCV following phagosome-lysosome fusion. Oxygen-
independent killing mechanisms include secretion of small bactericidal peptides and acidification 
of the phagolyssome (Jones 1997). In turn, macrophages present peptides derived from 
Salmonella on major histocompatibility complex class II (MHC II) for CD4 T cell activation 
(Bellet et al., 2013).  
Multiple studies demonstrate that infection of mice with Salmonella induces a Th1 
response, characterized by the production of large amounts of IFNγ. However, there are also 
reports indicating that under certain conditions infection with attenuated Salmonella can induce 
Th2 responses, characterized by the production of IL-4 and increased serum levels of IgE 
(Ramarathinam 1991). The importance of IFNγ in controlling Salmonella was demonstrated in 
mouse mutants deficient in IFNγ receptors, where Salmonella had uncontrolled access to host 
cell colonization (Mittrucker and Kaufmann 2000). 
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1.2 Capsular Polysaccharides 
1.2.1. Importance and Function 
 
The extracellular matrix of bacteria is composed of many components including proteins, 
lipids, and carbohydrates. Carbohydrates, namely extracellular polysaccharides: 
lipooligosaccharides (LOS), lipopolysaccharides (LPS), capsular polysaccharides (CPS), teichoic 
acids, lipoteichoic acids, glycoproteins, and peptidoglycans are found in various Gram-negative 
and Gram-positive bacteria (Upreti et al., 2003). CPS are unique and distinct from LPS in several 
ways. First, CPS does not contain Lipid A associated with the LPS core region. In some bacteria 
CPS have a lower net charge than LPS allowing separation on ion exchange chromatography. 
CPS usually has several hundred more repeat units, thus higher molecular weight, than LPS 
molecules. In Salmonella, CPS are partially substituted with a glucose side chain, for an example 
on tyvelose in S. Enteritidis and on abequose in S. Typhimurium, while this modification is only 
found on galactose on LPS molecules (Snyder et al., 2006). 
CPS are highly hydrated molecules containing 95%-99% water. They are made up of homo 
or heteropolymers of both organic and inorganic molecules linked together by glycosidic bonds 
(De Rezende et al., 2005; Costerton et al., 1981; Roberts 1996). The structural diversity and the 
presence or absence of immunological epitopes on CPS arises from the type of monosaccharides 
involved, variations in the glycosidic linkages between sugar monomers, number of carbon 
atoms forming the ring structure (furanose or pyranose form) of sugars, configuration of the 
anomeric center of the sugar molecule, presence of organic and inorganic molecules, 
introduction of side chains, and enantiomeric form (D or L form) of sugars (Mazmanian and 
Kasper 2006; Roberts 1996). 
CPS are often associated with virulence, provide barrier protection, desiccation resistance, 
innate and adaptive immune evasion, and act as lubricating agents and reduce friction over solid 
surfaces. For example, CPS facilitate swarming by Proteus mirabilis on solid surfaces (De 
Rezende et al., 2005). In addition, CPS can allow bacterial adherence to host cells, surfaces, and 
to each other; thereby facilitating biofilm formation and colonization (Costerton et al., 1987). 
Biofilm formation is highly ubiquitous and provides bacteria with nutritional advantages, 
protection from bacteriophage infection, and phagocytic protozoa (Ledeboer and Jones 2005; 
Roberts1996). It had been shown that capsulated E. coli, Acinetobacter calcoaceticus, and 
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Erwinia stewartii strains are more resistant to desiccation than non-capsulated strains. (Ophir and 
Gutnick 1994) 
Polysaccharide capsules, being associated with the cell surface, are able to regulate 
interactions between the bacterium and the environment. During capsule biosynthesis, activated 
precursor molecules (nucleotide monophosphate and diphosphate sugars) are assembled together 
by inner membrane enzymes to form the growing polysaccharide. Following this, capsule 
specific translocation proteins move the newly synthesized polysaccharide through the periplasm 
and across the outer membrane to the surface of the cell. Recent studies have indicated the 
presence of trans-envelope assembly complexes that coordinate simultaneous biosynthesis, 
export and translocation of the polysaccharide (Whitfield 2006). In some instances identical 
translocation pathways are used for certain capsular polysaccharides and LPS O-antigens 
(Whitfield et al., 1997).  
CPS are mainly attached to the cell through covalent linkages to lipid A molecules or 
phospholipids, while EPS are released to the cell surface and are often involved in slime (Roberts 
1996). However, though rarely, CPS can be released from the cell due to poor stability of the 
phosphodiester interactions between the CPS and the cell surface phospholipid molecules. 
Similarly, at times, EPS can remain tightly associated with the cell surface (Troy et al., 1971).  
Several studies have shown that carbohydrate antigens (i.e. CPS) are T cell-independent 
activators of B cells. Consequently, CPS antigens often induce IgM responses without a 
detectable level of IgG production (Figure 1.2.1A). The absence of antibody class switching 
from IgM to IgG and the inability to produce higher titers of antibody upon subsequent exposure 
to the antigen are hallmarks of T cell-independent antigens (Mazmanian and Kasper 2006). 
However, conjugation of polysaccharides to proteins can lead to T cell activation, memory B cell 
production, and development of polysaccharide specific immune responses (Figure 1.2.1B) 
(Sood and Fattom 1998). 
Capsules can serve different purposes and have differing immunogenicity in different 
bacteria. CPS producing bacteria are highly diverse and include both animal and plant pathogens. 
Some examples of CPS producing bacteria include: Escherichia coli, Salmonella Typhi, non-
typhoidal Salmonella serovars such as Typhimurium and Enteritidis, Shigella spp., Neisseria 
spp., Vibrio spp., Streptococcus spp., Cryptococcus neoformans, Staphylococcus aureus, 
Campylobacter jejuni, Bacteroides fragilis, Haemophilus influenza, Aeromonas Salmonicida, 
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Acetobacter methanolicus, Burkholderia mallei, and Francisella tularensis (Sukupolvi-Petty et 
al., 2006; Weiss et al., 2007; Gibson et al., 2006; DeShazer et al., 2001; Laxalt and Kozel 1979; 
Karlyshev and Wren 2000; Nelson et al., 2007; Fournier et al., 1984; Mazmanian and Kasper 
2006) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.1: Antibody production in response to polysaccharide antigens. (A) Polysaccharide antigens alone 
lead to IgM production, while (B) polysaccharide-protein conjugated antigens lead to IgG production and immune 
memory. Figure extracted from Mazmanian and Kasper 2006, reproduced with kind permission from Nature 
Publishing Group. 
 
The following is a look at the capsules and their characteristics in few selected bacteria. 
Historically, classification of capsules had started with E. coli, which has over 80 different CPS, 
known as K antigens (Orskov and Orskov 1992). Certain K antigens have identical 
polysaccharide chains, and only differ in the modifications of the polysaccharides (Vann et al., 
1983). In general, expression of a given type of CPS is associated with a unique infection. For a 
example, K1 antigen expressing E. coli are the primary cause of neonatal meningitis (Roberts 
1996). Interestingly, chemically identical capsular polysaccharides can be produced by different 
genera of bacteria. For an example, E. coli K1 CPS is identical to Neisseria meningitides group 
B CPS, and E. coli K18, 22, and 100 CPS are identical to Haemophilus influenza serotype b CPS 
(Grados and Ewing 1970; Roberts 1996). 
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Classification systems of E. coli were first developed by Kauffman in 1940 and were based 
on O, K and H antigens (discussed 1.1 “Introduction to Salmonella”). Since then, the 
classification scheme had seen many changes. Whitfield and Roberts have introduced an updated 
version of this system based on genetic and biosynthetic criteria (1999). The primary advantage 
of this new system is that it is not based on serological assignment and polysaccharide structure. 
According to this classification system capsules are categorized into four groups (Table 1.2.1). 
As observed by Whitfield and Roberts even though all polysaccharide K antigens form a capsule 
structure, all capsules are not composed of K antigens.  
Group 1 capsules are acidic polysaccharides containing uronic acid and tend to be similar 
in structure, and are often inaccurately classified as colanic acid (Whitfield 2006). The most 
prominent feature distinguishing group 1 capsules and colanic acid is that wild-type bacterial 
isolates are unable to produce colanic acid when grown at 37oC on common lab media (Whitfield 
2006). Group 4 capsules, despite many similarities, are far more diverse than group 1 capsules. 
Interestingly, group 4 capsules were previously classified as group 1 capsules and as a result 
became known as the ‘O-Antigen capsules’ (Goldman et al., 1982). One example is the group 4 
representative K40 antigen that was assigned to group 1 due to the presence of acetamido sugars 
in its repeat unit. K40 antigen was then shown to be surface expressed as smooth LPS and as 
unlinked O-antigen capsule and was reclassified in to group 4 (Roberts 1996; Amor and 
Whitfield 1997). This confusion in classification has arisen since K40 antigen is co-expressed 
with a neutral LPS linked polymer such as O8 or O9 antigen (Whitfield and Roberts 1999). 
Group 1 and 4 antigens are subgrouped into KLPS and capsular K antigens, where KLPS is made 
up of low molecular weight K antigenic oligosaccharides containing few repeat units and are 
linked to the cell surface through lipid A. KLPS, however, are different from LPS with the 
serological O-antigen found on the same cell (Whitfield 2006). Capsular K antigens are made up 
of high molecular weight antigens that form the capsule structure responsible for masking O 
antigen in serotyping. These capsular K antigens are not linked to lipid A core as in LPS 
molecules (Whitfield and Roberts 1999). When bacteria produce a group 4 capsule as the only 
serotype specific polysaccharide, it is classified as the O-antigen of that isolate (Whitfield 2006). 
Group 2 capsules are linked to the cell surface through α-glycerophosphatidic acid. In 
some bacteria Kdo (CMP-Kdo synthetase is involved in the biosynthesis of LPS) provides a link 
between the phospholipid and the polysaccharide. Expression of group 2 capsules is significantly 
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influenced by the temperature (Whitfield and Roberts 1999). Group 3 capsules are largely similar 
to group 2 capsules (Whitfield and Roberts 1999). During translocation, group 1 and 4 capsule 
assembly occur at the periplasmic face of the plasma membrane, while group 2 and 3 capsule 
assembly occur at the cytoplasmic face of the plasma membrane. In the assembly of capsules 
from all four groups, the sequential action of glycosyltransferases joins individual repeat units 
together elongating the polysaccharide (Whitfield and Roberts, 1999). 
 
 
Characteristic 
 
Group 
 
 
1 
 
 
2 
 
3 
 
4 
Former K antigen 
group 
 
1A II I/II or III IB (O-Antigen 
capsules) 
Co-expressed with 
O serogroups 
 
Limited range Many Many Often O8, O9, but 
sometimes none 
Co-expressed with 
colanic acid 
 
No Yes Yes Yes 
Thermostability 
 
Yes No No Yes 
Thermoregulated 
(not expressed 
below 20oC) 
 
No Yes No no 
Terminal lipid 
moiety 
 
Lipid A core in 
KLPS; unknown for 
capsular K antigen 
 
α-
Glycerophosphate 
α-
Glycerophosphate 
(hypothetical) 
Lipid A core in 
KLPS; unknown for 
capsular K antigen 
 
Genetic locus 
 
cps near his and 
rfb 
 
kps near serA kps near serA rfb near his 
Polymerization 
system 
 
Wzy-dependent Processive Processive Wzy-dependent 
Direction of 
polymer chain 
growth 
 
Reducing terminus Non-reducing 
terminus 
Non-reducing 
terminus 
(hypothetical) 
Reducing terminus 
Trans-plasma 
membrane export 
system 
 
Wzx (PST) ABC-2 exporter ABC-2 exporter 
(hypothetical) 
WZx (PST) 
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Translocation 
proteins 
 
Wza, Wzc KpsD, KpsE 
(KpsF may be 
involved) 
 
KpsD (KpsE may 
be involved) 
Unknown 
Elevated levels of 
CMP-Kdo 
synthetase 
 
No Yes No No 
Positively 
regulated by the 
Rcs system 
 
Yes No No No 
Model system(s) 
 
Serotype K30 Serotypes K1, K5 Serotypes K10, 
K54 
Serotypes K40, 
O111 
Similar to capsules 
in  
 
Klebsiella, 
Erwinia 
Neisseria, 
Haemophilus 
Neisseria, 
Haemophilus 
Many genera 
 
Table 1.2.1: Classification of E. coli capsules. Classification is based on biosynthesis and assembly systems. Rcs 
system plays an important role in late stages of biofilm development. CMP-Kdo synthetase is involved in the 
biosynthesis of LPS. Table adopted from Whitfield and Roberts 1999, and Whitfield 2006. 
 
In E. coli, expression of genes for the biosynthesis of EPS colanic acid, known as cell 
surface slime, is increased in the face of harsh environments and desiccation (Ophir and Gutnick 
1994). Despite the lack of concrete evidence in the mechanisms behind regulation of capsule 
expression, it is hypothesized that reduced external osmolarity act as a signal to increase capsule 
production (Roberts 1996). In support of this argument, it had been shown that reduced external 
osmolarity leads to increased expression of Vi antigen in S. Typhi and anionic polysaccharide 
alginate expression in Pseudomonas aeruginosa (Pickard et al., 1994; Berry et al., 1989). 
There are two types of CPS found in Salmonella; the Vi capsule (also known as Vi 
antigen) associated with S. Typhi, and the O-Antigen capsule associated with NTS. The Vi 
capsule increases virulence and disease severity of S. Typhi infection by interfering with 
neutrophil chemotaxis and bacterial clearance (Wangdi et al.2014; De Jong et al., 2012). 
Deletion of genes for Vi capsule biosynthesis can remarkably enhance the neutrophil chemotaxis 
in vitro. In addition, it had been shown that Vi capsule prevent complement activation through 
alternative pathway, as C3b is unable to deposit on the capsule surface and promote 
opsonophagocytosis (Wangdi et al., 2014; Wilson et al., 2011). It had also been demonstrated 
that Vi capsule promotes immune evasion by masking LPS molecules and preventing their 
recognition through pathogen recognition receptors (PRR). As a consequence S. Typhi does not 
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induce neutrophil influx and is able to disseminate systemically and cause a persistent infection 
(De Jong et al., 2012). Furthermore, the capsule-mediated suppression of TNF-α production by 
human monocytes lead to low serum concentrations of pyrogenic cytokines, and thereby prevent 
the development of septic shock (Raffatellu et al., 2006; Hirose et al., 1997). 
The O-Antigen capsule produced by NTS is co-regulated with cellulose and fimbriae to be 
part of the ECM. The group 4 O-Antigen capsules were shown to be important for attachment to 
surfaces, colonization, and desiccation resistance (Gibson et al., 2006). S. Typhimurium O-
Antigen capsule was shown to be expressed both at lower and higher temperatures indicating that 
the capsule may play a role in bacterial survival inside and outside the host, as had been 
described for other bacterial species, such as Hyphomonas strain MHS-3 (Quintero and Weiner 
1995). Mutations in O-Antigen capsule assembly and translocation gene, yihO, or cellulose 
synthesis gene, bcsA, significantly reduced the colonization of alfalfa sprouts by NTS (Barak et 
al., 2007). In addition, the promoter for O-Antigen capsule biosynthesis was expressed during in 
vivo infection of mice (White et al., 2008). 
Campylobacter jejuni (C. jejuni) produces LOS and CPS that are genetically and 
biochemically similar to polysaccharide capsules in other Gram-negative bacteria (Karlyshev and 
Wren 2001). Due to the presence of hypervariable polysaccharide biosynthesis genes, the 
structure of these polysaccharide monomers can vary between C. jejuni strains. These heat stable 
groups 2 or 3 CPS are part of the Penner antigen used for C. jejuni serotyping. It had been shown 
that C. jejuni CPS can be released to the surrounding environment in either naïve or lipid free 
form depending on the presence or absence of deoxycholate; a component of bile salt. Even 
though the specific purpose of released EPS is unknown, it is regarded as important for survival 
and pathogenesis of C. jejuni in foreign environments (Karlyshev and Wren 2001). Treatment of 
C. jejuni CPS with phospholipase release a lipid free product to the medium indicating that these 
CPS are substituted with a phospholipid inplace of a lipid A molecule (Karlyshev and Wren 
2001). 
Another frequently researched CPS is of Staphylococcus aureus (S. aureus). Clinical 
isolates of S. aureas are classified in to eight groups based on their CPS. The type 8 CPS is the 
most prevalent among bacteremic isolates and confers resistance to complement mediated 
opsonisation and phagocytosis (Fournier et al., 1984).  
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Bacteroides fragilis (B. fragilis) produced zwitterionic CPS was able to activate CD4+ T 
cells and correct immune defects such as dysregulated systemic cytokine production found in the 
absence of bacterial colonization and CD4+ T cell reduction in splenic lymphocyte populations 
(Mazmanian and Kasper 2006). It had also been shown in immunogenicity studies that 
administration of B. fragilis CPS alone protects Wistar rats against subsequent infection with B. 
fragilis (Kasper et al., 1979) 
Although CPS are often associated with Gram negative bacteria, many Gram-positive 
bacteria synthesize lipoteichoic acids or teichoic acids containing sugar alcohols with 
phosphodiester linkages. These sugar alcohols play a key role in attachment of bacteria to 
surfaces and in their interactions with host innate and adaptive immune systems (Kenzel and 
Henneke 2006). 
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1.3 Vaccines 
1.3.1 Polysaccharide Vaccines 
 
Polysaccharide vaccines are composed of capsular polysaccharides from Gram-negative 
bacteria and are classified as inactivated subunit vaccines. To date pure polysaccharide vaccines 
have been produced for four encapsulated bacteria: Streptococcus pneumonia (pneumococcus), 
Neisseria meningitides (meningococcus), Haemophilus influenzae type b (Hib) and Salmonella 
Typhi (Pollard et al., 2009). The adaptive immune response to polysaccharide antigens is usually 
T-cell independent, implying that polysaccharides are capable of activating B cells in the absence 
of T helper cells (MacLennan et al., 2014). However, the lack of T cell induction and in turn 
failure of B cell stimulation by T cells result in the absence of immunoglobulin class switching, 
induction of memory B cells, affinity maturation, prolonged antibody response, and lead to 
hyporesponsiveness to subsequent vaccination and/or to natural infection. In addition T cell 
independent antigens, such as polysaccharides, are poorly immunogenic in infants and young 
children under the age of two (MacLennan et al., 2014). 
Polysaccharide capsules are composed of numerous identical epitopes in close proximity 
within each other and can crosslink immunoglobulin receptors on the surface of B cells for B cell 
activation. However, these polysaccharides are not processed and presented on MHC class II 
molecules for T helper cell activation (Lesinski and Westerink 2001). Although polysaccharide 
antigens are unable to induce the production of memory B cells they can activate previously 
formed memory cells, leading to terminal differentiation of memory cells into plasma cells. 
However, this depletes the reservoir of memory B cells specific for a given polysaccharide 
antigen and could result in a condition called hyporesponsivness, which is the inability to 
respond to subsequent exposure to the same antigen due to lack of memory B cells (Blanchard-
Rohner and Pollard 2011). Repeated administration of the same polysaccharide antigen(s) can 
exacerbate this situation. In contrast, repeated administration of most protein vaccines leads to a 
booster effect resulting in progressively higher antibody titers. In addition, antibody produced in 
response to polysaccharide antigens are predominantly IgM and have less functional activity than 
IgG antibody (Blanchard-Rohner and Pollard 2011). 
Marginal zone (MZ) B cells and B1 cells (and naïve B cells to a lesser extent) are the most 
important at recognizing polysaccharide antigens. These cells are able to produce low affinity 
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IgM (natural) antibodies in response to polysaccharides. B1 and MZ B cells have higher 
expression of CD21 receptor and are able to bind to complement coated polysaccharides 
(Blanchard-Rohner and Pollard 2011). The spleen, being a vital organ of the immune system, is 
crucial for MZ B cell production and their survival (Kruetzmann et al., 2003). For example, 
individulas with congenital asplenia, splenic hypofunction or who have undergone splenectomy 
are highly susceptible to encapsulated bacterial diseases, as they have depleted number of 
functional MZ B cells and are defective at removing opsonized bacteria (Blanchard-Rohner and 
Pollard 2011). Furthermore, the immune response to polysaccharide antigens is age-dependent as 
children under the age of two are also susceptible to encapsulated bacteria, since prior to this age 
the MZ is not fully developed and is unable to facilitate the development of B cells (Kruschinski 
et al., 2004). In addition, the presence of maternal antibody and the effect of suppresser T cells 
also contribute to the lack of response to polysaccharide antigens in infants (Sood and Fattom 
1998). However, some zwitterionic polysaccharides (have both positive and negative charge) 
such as capsules from Bacteroides fragilis, S. pneumonia serotype 1 and 3, and N. meningitides 
serogroup A possesses characteristics of T cell dependent antigens and are presented in an MHC 
class-II dependent manner. These antigens are immunogenic in even infants and young children 
(Jokhdar et al., 2004; Kalka-Moll et al., 2002). 
Since the late 20th century, polysaccharide vaccines have helped save lives of millions of 
people worldwide. However, there are several limitations associated with pure polysaccharide 
vaccines. These include: hyporesponsiveness, short term impact on bacterial carriage where 
individuals have been shown to carry bacteria for several months and even years without 
symptoms and remained communicable, and poor immunogenicity in children under the age of 
two (Wilder-Smith 2009). In addition, the response for polysaccharide antigens among two to 
five year old children, the elderly, and the immunocompromised individuals are not optimal, 
while these populations remain at an elevated risk of contracting bacterial diseases (Sood and 
Fattom 1998). Furthermore, pure polysaccharide vaccines are unable to provide herd immunity, 
which is a key element in prevention of invasive diseases. Herd immunity is achieved when the 
majority of a community is immunized against a given infectious disease, such that even those 
who have not received immunization are protected as the spread of the disease is contained 
(Vaccines.gov 2015). 
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Antibody titers induced in infants after immunization with N. meningitides serogroup C 
(MenC) vaccine fell below the threshold of protection in 50% of vaccinees by one year of age 
and only 12% of vaccinees maintained protection at four years of age (Snape and Pollard 2005). 
There is very little evidence that immunization of infants with the MenC vaccine confers 
protection beyond one year, as antibody titers decrease rapidly following infant immunization 
(Trotter et al., 2004). When administered after one year of age, polysaccharide vaccines induce a 
more persistent antibody response. However, sustained levels of protection were not observed 
until much later in childhood in many children (Snape et al., 2008). In addition, the decline in 
protective immunity following infant immunization was also noted for H. influenzae type b 
vaccine (Pollard et al., 2009). Therefore, the duration of protective immunity following 
immunization with polysaccharide antigens depends on the persistence of functional antibodies, 
maintenance of immunological memory, and establishment of herd immunity (Pollard et al., 
2009). 
To address the concerns of T-cell independent pure polysaccharide vaccines, in late 1980s 
it was discovered that chemical conjugation of the polysaccharide antigen to a carrier protein 
resulted in a polysaccharide-protein conjugate that was T cell dependent and highly 
immunogenic (Makela and Kayhty 2002). The first polysaccharide-protein conjugate vaccine 
was produced for H. influenzae type b. A conjugate vaccine for S. pneumonia was produced in 
2000 and for N. meningitides in 2005. Conjugate vaccines have resulted in a significant reduction 
in the disease burden associated with encapsulated bacteria when these vaccines have been 
introduced in the immunization schedules of multiple countries (Ramsay et al., 2003(a); Heath 
and McVernon 2002). These vaccines are effective due to their ability to induce memory B cell 
production, induction of immunity in children under the age of 2, ability to provide herd 
immunity, and the capacity to overcome hyporesponsiveness (Heath and McVernon 2002; 
Ramsay et al., 2003(b)). 
Although immunogenic, the magnitude of the antibody response to conjugate vaccines and 
their persistence is age-dependent. It had been observed that in infants and toddlers, the serum 
antibody concentration following immunization with conjugate vaccines declined rapidly even 
though the immunological memory lasted much longer (Borrow et al., 2010; Snape et al., 2006). 
Despite multiple doses being administered to infants, the effectiveness of MenC and Hib 
vaccines have declined after one year from initial immunization in the absence of a booster dose 
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after the age of one (Ramsay et al., 2003(a); Trotter et al., 2004). The importance of persistent 
serum antibodies was demonstrated in vaccine failures where despite being immunized and 
having memory B cells, some children succumbed to meningococcal and Hib infections 
(Auckland et al., 2006; McVernon et al., 2003). This is explained by the fact that encapsulated 
bacteria are able to invade and cause disease within a few hours, while memory B cells require 
several days to mount a protective antibody response (Snape et al., 2006; Blanchard-Rohner et 
al., 2008). Thus, induction of immune memory alone is not sufficient to protect against 
encapsulated bacterial infections and require high titers of persistent serum antibodies. 
Nonetheless, upon the introduction of the Hib conjugate vaccine in 1988, the disease burden 
among children in the United States declined by 50% per year from 1988 to 1991 (Schoendorf et 
al., 1994). In clinical trials, a reduction in the nasal carriage with vaccine-specific S. pneumonia 
serotypes in children was also observed following immunization with two multivalent 
pneumococcal conjugate vaccines (Dagan et al., 1996; Sood and Fattom 1998). Furthermore, in 
older children and adults, even a single dose of a conjugate vaccine lead to highly persistent anti-
capsular antibodies (Snape et al., 2006; Snape et al., 2008). In Vaccine development bi-, tri-, 
tetra-, and/or multi- ‘valent’ means that the given number of separate protein or polysaccharide 
antigens is combined together in a single vaccine. 
Although pure polysaccharide vaccines have been effective at saving lives for years, 
conjugation of polysaccharide antigens from H. influenzae type b, S. pneumonia, N. 
meningitides, and S. Typhi have generated T cell-dependent antigens that are effective in even 
the very young children (Plotkin 2003). The first polysaccharide vaccine against N. meningitides 
was used in the United States in 1984, and was given to all the new military personnel upon 
entering basic training. Upon the administration of this tetravalent polysaccharide vaccine, no 
cases of meningococcal infections related to serogroup Y or W135 had been reported in the 
United States military (Sood and Fattom 1998). However, this vaccine was poorly immunogenic 
among infants and young children (Sood and Fattom 1998). A quadrivalent vaccine containing 
polysaccharide antigens from N. meningitides serogroup A, C, Y, and W135 was initially 
licensed in the United States in 1981. A bivalent vaccine containing polysaccharide antigens 
from serogroup A and C is also available in some countries (Pollard et al., 2009).  
Serogroup C (MenC) conjugate vaccine containing either tetanus toxoid or cross reacting 
material 197 (CRM197; which contains a glycerine to glutamic acid point mutation at position 52 
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in the A subunit of diphtheria toxoid) was first licensed in the United Kingdom in 1999, while a 
quadrivalent A, C, Y, and W135 diphtheria toxoid conjugate vaccine became first available in 
North America in 2005 (Nair 2012). In addition, several other conjugate vaccines are currently 
being produced and in clinical trials including A, C, Y, and W135 conjugated to tetanus toxoid 
and A, C, Y, and W135 conjugated to CRM197 (Pollard et al., 2009). As serogroup B capsular 
polysaccharide is highly similar to the cell surface glycoprotein on fetal brain tissue and result in 
tolerance and reduced immunogenicity, development of a polysaccharide based vaccine, either 
pure or conjugate, remains a significant hurdle in vaccine development against N. meningitides 
serogroup B (Nair 2012). One study compared the effectiveness between the meningococcal 
serogroups A and C pure polysaccharide vaccine (MACP) vs the conjugate vaccine against 
serogroup C (MCC), since the use of MACP vaccine had raised concerns that this vaccine is 
leading to hyporesponsiveness to serogroup C polysaccharide antigen (Richmon et al., 2000). In 
this study individuals who received a primary immunization of MACP were given a second 
immunization of either MACP or MCC. Those who received MCC produced significantly higher 
titers of IgG antibody than the individuals who received MACP as the second dose. In addition, 
the response to the second MACP vaccine was considerably lower than that following the first 
immunization. This supported the observation that repeated vaccination with MACP vaccine is 
ineffective and leads to hyporesponsiveness towards the meningococcal serogroup C 
polysaccharide antigens in adults. However, it was possible to overcome the MACP induced 
hyporesponsiveness with subsequent vaccination with MCC (Richmon et al., 2000). 
A pure polysaccharide hexavalent vaccine against S. pneumonia was first licensed in 1947, 
but was eventually withdrawn due to low sales and lack of acceptance (Sood and Fattom 1998). 
A polyvalent vaccine containing 14 polysaccharide antigens became available in the United 
States in 1977, and was recommended for at risk populations including the elderly, 
immunocompromised patients, and individuals with chronic cardiac, pulmonary, or renal 
diseases (Shapiro et al, 1991). The vaccine had 93% efficacy following three years from initial 
immunization among immunocompetent individuals under 55 years of age. However in 
vaccinees over 85 years of age, the efficacy was only 46% after three years (Shapiro et al., 
1991). Furthermore, the vaccine’s efficacy was shown to decline over time. However, this can be 
explained by the waning immunity and the exposure to additional pneumococcal serotypes over 
the years (Halloran et al., 1991; Shapiro et al., 1991).  
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The widely used current polyvalent pneumococcal vaccine, licensed in 1983, is made of 23 
immunologically distinct polysaccharide antigens and is effective in preventing disease in 
immunocompetent individuals (Shapiro et al., 1991). In addition, there are several other 
pneumococcal vaccines that are also in use. These include the seven-valent conjugate vaccine 
(PCV7) that contain the serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, and the ten-valent conjugate 
vaccine additionally containing serotypes 1, 5, and 7F. The eleven-valent and thirteen-valent 
conjugate vaccines are currently undergoing clinical trials (Pollard et al., 2009; Nair 2012). As 
there are multiple pathogenic S. pneumonia serotypes, development and conjugation of each 
polysaccharide to carrier proteins remains a complex process and is quite challenging (Nair 
2012). 
A pure polysaccharide vaccine for H. influenzae type b (Hib) was first used in the United 
States in 1985, but due to poor efficacy in children younger than 18 months of age and 
immunological variability in older children, 88% to -69%, where a negative efficacy means 
higher disease risk for the immunized population compared to the non-vaccinated group, the 
vaccine was withdrawn from use in 1988 (Robbins et al., 1992). Pure polysaccharide Hib 
vaccine elicited an age-dependent antibody response, where older children and adults developed 
protective levels of antibodies with long lasting efficacy (Rodrigues et al., 1971; Smith et al., 
1973), while young children generate protective, but lower levels of antibody titers that decrease 
after one year from initial immunization. In addition, infants, being the most susceptible to Hib 
infection, were non-responsive to the pure polysaccharide Hib vaccine (Smith et al., 1973; 
Robbins et al., 1992). 
In 1989 the pure polysaccharide vaccine was replaced by a polysaccharide-protein 
conjugate vaccine linking the Hib polysaccharide polyribosylribitol phosphate to diphtheria 
toxoid, tetanus toxoid, or meningococcal outer membrane protein (Pollard et al., 2009). The 
United Kingdom had introduced the Hib conjugate vaccine to the infant immunization schedule 
in 1992 (Pollard et al., 2009). These vaccines are administered to date either alone or in 
combination with other vaccines for the protection of preschool children (Pollard et al., 2009). 
Meningitis and other infections caused by Hib have been completely eliminated in both 
vaccinated and unvaccinated children due to herd immunity in countries that have incorporated 
Hib conjugate vaccine in the infant immunization schedule (Adams et al., 1993; Robbins et al., 
1992). The antibody subclass highly induced and mainly sustained by pure polysaccharide Hib or 
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Hib conjugate vaccines in adults is IgG2. Subsequent immunizations with pure polysaccharide 
Hib or Hib conjugate vaccines do not generate booster responses in adults (Schneerson et al., 
1986; Robbins et al., 1992). However, multiple immunizations with Hib conjugate vaccine elicit 
booster responses in infants with elevated IgG1 titers (Parke et al., 1991; Claesson et al., 1988; 
Robbins et al., 1992).  
The pure polysaccharide vaccine against S. Typhi is made up of the Vi capsular 
polysaccharide antigens. The serum antibody towards Vi antigen is mostly IgM driven. In one 
study only 2 out of 32 subjects generated sufficient amount of IgG towards the Vi antigen 
(Tacket et al., 2004). However, in typhoid fever endemic regions, immunization with the Vi 
vaccine resulted in 55% and 75% efficacy rates among adults and children over the age of 5 
years (Sood and Fattom 1998). Vaccines for Typhoid fever are discussed in more detail in 
Section 1.3.2 “Salmonella Vaccines: Past, Present, and Future”. 
Another polysaccharide-protein conjugate vaccine candidate is Shigella O-specific 
polysaccharide (O-SP) domain of LPS. It had been shown that serum IgG to O-SP induced 
protective immunity to Shigellosis (Passwell et al., 2001). In order to increase immunogenicity in 
young children, O-SP was covalently linked to carrier proteins. In one clinical study it was 
shown that conjugation of Shigella sonnei and Shigella flexneri 2a O-SP to succinylated 
Pseudomona aeruginosa exotoxin A mutants or Corynebacterium diphtheria toxin mutants was 
highly immunogenic, and resulted in high titers of serum IgG against O-SP within one week of 
immunization (Passwell et al., 2001). Out of the different vaccine candidates P. aeruginosa 
conjugate vaccine resulted in the highest IgG titers and the highest efficacy was observed for S. 
sonnei conjugate vaccine at 74% (Passwell et al., 2001; Ferreccio et al., 1991). Following 
immunization with S. sonnei conjugate vaccine, IgG and secretary IgA antibody had been 
detected in urine, implying that this vaccine was able to induce mucosal immunity (Cohen et al., 
1996). In addition, a single immunization with S. sonnei rEPA conjugate vaccine conferred 
specific protection against shigellosis in young adults (Cohen et al., 1997). 
Staphylococcus aureus type 5 and type 8 capsular polysaccharides are of high clinical 
importance. Immunization with S. aureus capsular polysaccharide conjugate vaccines generated 
high titers of specific antibodies. These antibodies were able to recognize variations in capsular 
polysaccharide that occur among clinically significant S. aureus isolates (Fattom et al., 1998). In 
addition, the Vibrio cholera O1 serotype Inaba polysaccharide and cholera toxin conjugate 
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vaccine was shown to induce serum anti-LPS IgG with bactericidal activity. V. cholera specific 
antibodies, whether acquired through natural immunity, following colonization by the bacteria, 
or after immunization, are all directed against the LPS molecules (Gupta et al., 1998). 
Furthermore, antibody generated against the O-specific polysaccharides of V. cholera serotype 
Inaba were able to cross recognize polysaccharides from V. cholera serotype Ogawa (Gupta et 
al., 1998). In another study, S. Typhimurium O-antigens 4 and 12 covalently linked to bovine 
serum albumin (BSA) when administered with Freund adjuvant led to the production of 
significantly high O4 specific antibody titers in rabbits; comparable to those elicited by the 
immunization with heat killed bacteria (Svenson and Lindberg 1981). 
 
1.3.2 Salmonella Vaccines: Past, Present and Future 
 
Development of an effective Salmonella vaccine for humans remains a pressing issue 
today. Salmonella are able to survive both extracellularly and intracellularly within monocytes 
and macrophages. This is a significant challenge for vaccine development, as both humoral and 
cell mediated immunity are needed to efficiently target and clear both extracellular and 
intracellular bacteria (Mastroeni et al., 1993; Salerno-Goncalves et al., 2002). Antibodies 
mediate pathogen killing through opsonisation, thereby facilitating phagocytosis and preventing 
the spread of disease through blood (Mastroeni et al., 2009). T cells, on the other hand, are 
involved in destroying Salmonella residing within phagocytic cells (Blanden et al., 1966; 
Mackaness et al., 1966) (discussed in detail in 1.1.3 “Clinical Manifestation’). The requirement 
of both arms of the immune system had been demonstrated through animal studies, where mice 
lacking T cells were unable to control Salmonella infections (Sinha et al., 1997). In other studies, 
passive transfer of specific antibodies provided significant clearance of Salmonella in vivo 
(Mastroeni et al., 1993; McSorley and Jenkins 2000).  
The first vaccine against Salmonella was developed in 1896 against S. Typhi, and was used 
by British and United States military personnel. Over the next 100 years the vaccine had been in 
use, this inactivated whole cell vaccine had dramatically reduced the number of deaths associated 
with typhoid fever (MacLennan et al., 2014; Hawley and Simmons 1934). Although this vaccine 
had an efficacy of 73% over three years post immunization, it also had high reactogenicity and 
therefore its use was discontinued (Engels et al., 1998; Ivanoff et al., 1994; Wahdan et al., 1975). 
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Currently, there are two vaccines against S. Typhi: Ty21, a live attenuated vaccine, and Vi 
capsule-based vaccine made up of purified Vi capsular polysaccharides (Table 1.3.2(a)). Even 
though Ty21 strain was derived from non-specific chemical mutagenesis of the S. Typhi Ty2 
strain, Ty21 does not express Vi capsule, and as a result, the immune response to live attenuated 
Ty21 strain is not directed against the Vi capsule (Germanier and Furer 1975). The Ty21vaccine 
requires three doses to induce best protective immunity and in combination the three doses have 
an efficacy of 51% (Engels et al., 1998; Fraser et al., 2007). This vaccine is not thermostable 
over long periods of time and requires a cold chain. This is a setback as the vaccine is most 
needed in developing countries where access to refrigeration is difficult (MacLennan et al., 
2014). It had been shown that freeze drying can increase the thermal stability of the vaccine, but 
this measure is currently not in place (Ohtake et al., 2011). Despite the Ty21vaccine being 
licenced to use in adults and children over five years, seroconversion is greatly reduced in young 
children compared to adults (Cryz et al., 1993). Nonetheless, the Ty21 vaccine can induce T cell 
immunity and had shown cross protection against S. Paratyphi B in clinical studies. In addition, 
in vitro cross protection had been shown for S. Paratyphi A and B (Pakkanen et al., 2012; Wahid 
et al., 2012). As the antibody response is mostly directed against the O:9 O-antigen epitope of S. 
Typhi, it had been shown that the Ty21 vaccine is able to elicit cross protective immunity against 
iNTS and NTS serovars also expressing the O:9 or O:9,12 epitopes (Pakkanen et al., 2014; 
MacLennan et al., 2014; Kantele et al., 2012). 
Although the immune response to the Vi capsule based vaccine is primarily directed 
towards the Vi capsule, recent evidence had indicated that the immune response could also be 
due to other Salmonella components in the vaccine (Kantele et al., 2012). However, the vaccine 
is considered to be non-immunogenic in infants, due to Vi capsule being a T-independent 
antigen. Therefore it is only licenced for children over 2 years of age (MacLennan et al., 2014). 
In contrast to Ty21 vaccine, the Vi capsule-based vaccine requires a single dose and has a 
efficacy of 55% over three years. This vaccine also requires a cold chain to prolong the life and 
effectiveness of the vaccine (MacLennan et al., 2014). It had been shown that following 
vaccination with Vi capsule based vaccine, circulating plasmablasts (immature plasma cells) 
express systemic homing receptors (L selectin), while vaccination with Ty21 vaccine lead to the 
expression of mucosal homing receptors (α4β7), as with natural infection (Kantele et al., 2012). 
No clinical trial had been performed to date to examine the efficacy and protection of these two 
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vaccines combined (MacLennan et al., 2014). However, several clinical trials have tested the 
efficacy and type of immune response mounted following immunization with inactivated whole 
cell Salmonella vaccine candidates (Nath et al., 1977; Rajagopalan et al., 1982). 
 
Name Description Developer Stage of Development 
Vaccines currently available and in development against S. Typhi 
Ty21a Live attenuated Vivotif (Crucell) Licensed for adults and 
children over 5 years 
Vi CPS Vi polysaccharide Typherix (GSK), Typhim Vi 
(Sanofi), Tybar Vi (Bharat 
Biotech), Typho Vi (BioMed) and 
Vax-tyVi (Finlay Institute), also 
manufactured by 6 other endemic 
countries 
Licensed for adults and 
children over 2 years 
Vi-TT Vi conjugate Peda-Typh (BioMed) Licensed in India 
Tybar-TCV (Bharat Biotech) Licensed in India 
Vi-rEPA Vi conjugate National Institutes for Health 
(NIH) 
Phase 3 
Lanzhou Institue (China) Licensed in China 
Vi-CRM Vi conjugate Novartis Vaccine Institute for 
Global Health (NVGH) 
(technology transfer to Biological 
E. Limited underway) 
Phase 2 
Vi-DT Vi conjugate International Vaccine Institute 
(IVI)/Shanta Biotech 
Phase 1 
Vi conjugated to 
fusion protein 
PsaA-PdT 
Vi conjugate Harvard Medical School Preclinical 
O:9-DT O:9 conjugate International Vaccine Institute 
(IVI) 
Preclinical 
M01ZH09 Live attenuated Emergent Biosolutions Phase 2 in adults and 
children; evaluation in S. 
Typhi human challenge 
CVD 909 Live attenuated University of Maryland Phase 2 
Ty800 Live attenuated Avant immunotherapeutics Phase 2 
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OmpC and OmpF Outer membrane 
protein 
Institute Mexicano del Seguro 
Social 
Phase 1 in Mexico 
  
Vaccines in development against S. Paratyphi A 
O:2-TT O:2 conjugate National Institutes for Health 
NIH) 
Phase 2 
Technology transfer from NIH to 
Lanzhou Institute (China) 
Phase 2 
Technology transfer from NIH to 
Chengdu Institute (China) 
Preclinical 
Changchun Institute of Biological 
Products 
Preclinical 
O:2-DT 
(development in 
combination with Vi-
DT conjugate against S. 
Typhi) 
O:2 conjugate International Vaccine Institute  
(IVI) (Seoul, Korea) 
Preclinical 
O:2-CRM 
(development in 
combination with Vi-
CRM conjugate against 
S. Typhi) 
O:2 conjugate Novartis Vaccine Institute for 
Global Health (NVGH) 
(technology transfer to Biological 
E. Limited underway) 
Preclinical 
VCD 1902 
(development in 
combination with CVD 
909) 
Live attenuated University of Maryland Phase 1 
 
Vaccines in development against invasive non-Typhoidal Salmonella (iNTS) 
O:4,5/O:9-flagellin O:4,5/O:9 
conjugate 
University of Maryland Preclinical 
O:4, 12-TT O:4-TT conjugate National Institutes for Health 
NIH) 
Preclinical 
Os-po O:4-porin 
conjugate 
National Bacteriology Laboratory, 
Stockholm 
Preclinical 
O:4,5/O:9-CRM O:4,5/O;9 
conjugate 
Novartis Vaccine Institute for 
Global Health (NVGH) 
Preclinical  
WT05 Live attenuated Microscience, Wokingham 
Berkshire 
Phase 1 
CVD 1921 and Live attenuated University of Maryland Preclinical  
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CVD 1941 
S. Typhimurium 
ruvB mutant 
Live attenuated Seoul National University Preclinical  
Salmonella hfq 
deletion mutant 
Live attenuated Indian Institute of Science 
Bangalore 
Preclinical  
SA186 Live attenuated Istituto Superiore di Sanita Roma Preclinical  
MT13 Live attenuated KIIT University Odisha Preclinical  
Various Live attenuated, 
DNA adenine 
methylase 
mutants 
University of California, Santa 
Barbara 
Preclinical  
Various Live attenuated, 
regulated delayed 
attenuation 
Arizona State University Preclinical 
Porins S. Typhimurium 
porins 
National Bacteriology Laboratory, 
Stockholm 
Preclinical 
OmpD Outer membrane 
protein 
University of Birmingham, UK Preclinical 
S. Typhimurium 
and S. Enteritidis 
GMMA 
Generalized 
Modules for 
Membrane 
Antigens 
Novartis Vaccine Institute for 
Global Health (NVGH) 
Preclinical 
 
Table 1.3.2(a): Vaccines currently in use and vaccine candidates being developed for humans against S. 
Typhi, S. Paratyphi A, and iNTS. Note that most vaccine candidates for S. Typhi are currently in clinical trials, 
while those for S. Paratyphi A and iNTS are still in preclinical trials. This is not a comprehensive list of all the 
vaccine candidates that are being tested. Table extracted from MacLennan et al., 2014, reproduced with kind 
permission from Human Vaccine & Immunotherapeutics. 
The Vi capsule-based vaccine primarily induces humoral immunity, since almost always 
polysaccharides are T-independent antigens and require conjugation to carrier proteins to induce 
T cell-dependent immune responses (Suz et al., 2014; Pollard et al., 2009). The importance of 
antibody in clearing S. Typhi infections was demonstrated by efficacy data for Vi capsule based 
vaccine and Vi conjugate vaccine candidate phase 3 studies (Engels et al., 1998; Fraser et al., 
2007; Lin et al., 2001; Thiem et al., 2011). A phase 3 study of a glycoconjugate vaccine 
combining S. Typhi Vi capsule with P. aeruginosa exoprotein A (Vi-rEPA), conducted over a 
decade ago in Vietnamese children between two and five years of age, found a 91% efficacy 
after 27 months and 89% efficacy after 46 months from primary immunization (MacLennan et 
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al., 2014). However, the delay in seeing new vaccines in the market is mainly due to a lack of 
commercial interest in developing vaccines against typhoid fever and iNTS disease, since these 
are largely diseases of low-income countries, which have little or no money to invest in vaccines 
(MacLennan 2013). New vaccines are expected to provide improved protection and efficacy, 
especially in young children, and to reduce the cost of delivery these vaccines are to be 
administered as part of the national Expanded Programmes on Immunization (MacLennan et al., 
2014). Vaccines for S. Typhi and/or S. Paratyphi are to be given at nine months, as disease peaks 
at two years of age, and vaccines for iNTS are to be given between 2 and 4 months of age, prior 
to the disease peak at one year of age (Podda et al., 2010; MacLennan et al., 2008; Feasey et al., 
2010). 
Although a humoral response is sufficient to clear S. Typhi infections, both antibody and 
cell-mediated immunity are required for proper clearance of iNTS. This had been shown in field 
studies in sub-Saharan Africa, where age-related prevalence of iNTS disease in children declined 
with acquisition of specific antibody (MacLennan et al., 2008). In addition, serum antibodies had 
shown in vitro bactericidal activity and oxidative killing of iNTS (MacLennan et al., 2008; 
Gondwe et al., 2010). It had also been demonstrated that O-antigen-based conjugate vaccine 
candidates can induce sufficient protection against otherwise lethal doses of Salmonella in mice 
(Simon et al., 2011; Watson et al., 1992). Passive transfer of monoclonal antibodies specific for 
O-antigen was also able to confer protection against lethal doses of Salmonella challenge (Carlin 
et al., 1987; Singh et al., 1996). Immunization of animals with heat-killed invasive African S. 
Typhimurium 313 strain leads to majority of antibody to be mounted against O-antigen (Rondini 
et al., 2013). On the other hand, the importance of cell-mediated immunity in clearing iNTS is 
apparent through the association between HIV infection and predisposition to iNTS, especially 
when the CD4+ count is below 200 cell/uL (Gordon et al., 2002). HIV is also known to increase 
susceptibility to NTS through dysregulation of cytokine response, humoral immunity, and 
disruption of the integrity of the gastrointestinal mucosa (Mackaness et al., 1966; Lazarus and 
Neu 1975). Therefore, vaccine candidates that induce protective mucosal immunity, preventing 
gastroenteritis and NTS invasion from the gastrointestinal tract, would be highly beneficial for 
HIV-infected individuals (MacLennan et al., 2014). 
Currently there are several different types of novel Salmonella vaccine candidates being 
tested (Table 1.3.2(a)) which fall in to three main categories: glycoconjugate, live attenuated, and 
 32 
subunit vaccines. Glycoconjugate vaccines covalently link a poorly immunogenic antigen, such 
as a bacterial surface polysaccharide, to a protein carrier molecule to activate CD4+ T cells. 
Thus, glycoconjugation is able to convert the Vi capsule or O-antigen of Salmonella from T 
independent to T-dependent antigens and facilitate the production of specific antibodies and 
memory B cells (MacLennan et al., 2014). For glycoconjugation most Salmonella vaccine 
candidates use the common carrier proteins tetanus toxoid, diphtheria toxoid, a nontoxic 
recombinant of diphtheria toxoid, or P. aeruginosa exoprotein A (rEPA) (MacLennan et al., 
2014). It had been proposed that glycoconjugate vaccines using Salmonella carbohydrates linked 
to Salmonella proteins could be more effective at inducing Salmonella-specific antibody than 
using exogenious carrier proteins, since antibody can be produced against both Salmonella 
protein and carbohydrate (Simon and Levine 2012; Svenson et al., 1979). In addition, 
conjugation to Salmonella proteins can also lead to the generation of Salmonella-specific T cells. 
It had been shown that conjugation of S. Typhimurium O:4 to its porins lead to better protection 
of mice upon challenge, instead of using porins alone or O:4 conjugated diphtheria toxoid 
(Svenson et al., 1979). As flagellin is the only Salmonella surface typing protein antigen it had 
been investigated for the ability to generate protective immunity. It had been shown in mice that 
immunisation with flagellin alone, or in conjugation with O-antigen lead to the induction of 
protection (Simon et al., 2011; Eom et al., 2013; Simon et al., 2013). For a example, 
immunization with O:4,5 and O:9 conjugated to Salmonella flagellin in iNTS vaccine candidates 
lead to enhanced protective immunity (Simon et al., 2011; Bobat et al., 2011). Flagellin, being 
the primary ligand for TLR5 activation, can signal to the innate immune system and lead to 
immunomodulatory effects in mice (Simon et al., 2013 Cunningham et al., 2004). One concern is 
that in some Salmonella serovars, such as in S. Typhimurium, flagellin can have phase variable 
expression and is not constitutively expressed during infection (MacLennan et al., 2014).  
Live, attenuated vaccines are able to induce both humoral and cellular immunity, and 
thereby facilitate Salmonella specific T cell responses. These vaccines are easy to deliver (orally) 
and can induce strong mucosal immune responses (Kantele et al., 2012). In addition, the 
availability of numerous Salmonella antigens on live bacteria (Table 1.3.2(b)) can allow the 
development of broad protective immune responses and even allow cross recognition between 
Salmonella serovars. The primary challenge with developing live attenuated vaccines is in 
balancing the level of immunogenicity with proper and sufficient level of attenuation 
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(MacLennan et al., 2014). Currently several live attenuated S. Typhimurium strains are being 
tested for their efficacy in preclinical and clinical studies (Table 1.3.2(a)). Also several 
recombinant Salmonella strains expressing heterologous antigens are being assessed for their 
ability to protect against various pathogens (Mittrucker and Kaufmann 2000). Furthermore, it 
will be useful to develop vaccines that require one or two doses to mount an optimal immune 
response, compared to the required three doses of the current Ty21 vaccine (MacLennan et al., 
2014). 
 
Mutated gene Gene function(s) 
galE Conversion of UDP-galactose to UDP-glucose 
aro Biosynthesis of PABA, DHB and aromatic aminoacids 
pur Biosynthesis of adenine 
htrA Protection against heat stress and oxidative stress 
cya/crp Biosynthesis of cAMP and expression of the AMP receptor 
ompR Regulation of the expression of outer membrane protein and Vi antigen 
ompC, ompF Biosynthesis of outher membrane proteins C or F 
phoP/phoQ Two-component system that is a key regulator of many virulence genes 
waaN Secondary acylation of lipid A 
recA, recBC DNA recombination and repair 
guaBA Biosynthesis of guanine nucleotides 
nuoG Expression of NADH dehydrogenase-I 
surA Biosynthesis of a peptidylprolyl-cis, trans-isomerase 
dam Expression of DNA adenine methylase 
 
Table 1.3.2(b): Salmonella genes mutated in live-attenuated vaccines. Immunization with live Salmonella 
mutated in these genes decrease the virulence and allow the induction of strong protective cell mediated and 
humoral immune responses. Table 1 of Mastroeni et al., 2001 with modifications, reproduced with kind permission 
from Elsevier. 
 
Protein-based subunit vaccines are composed of multiple antigenic epitopes, and can have 
broad coverage. A subunit approach is currently in use for multivalent pneumococcal and 
meningococcal conjugate vaccines. However, subunit vaccines, especially those using 
glycoconjugate technologies, are costly to produce and since most vaccines are to be used in the 
poorest countries, affordability remains a key factor in vaccine development. In order to balance 
the cost effectiveness, it had been proposed that multivalent vaccines composed of 5 to 6 
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antigens could provide cross protection against the majority of the iNTS serovars (Simon and 
Levine 2012). Another strategy to develop broad coverage, cross protective vaccines are to use 
highly conserved protein antigens produced through recombinant technology (Gil-Cruz et al., 
2009; Secundino et al., 2005; Salazar-Gonzalez et al., 2004). Proper antigens can be selected 
using bioinformatics analysis of whole genome sequences and reverse vaccinology (Sette and 
Rappuoli 2010). Examples of highly conserved protein antigens include flagellin and porins (i.e. 
OmpC, F, and D). Currently, recombinant and purified protein vaccine candidates are being 
tested against conserved protein epitopes (World Health Organization 2014).  Subunit vaccines 
can induce both T cell responses and antibody production; a balanced Th1-Th2 approach that is 
key to proper clearance of Salmonella. One of the downsides of subunit vaccines developed 
through recombinant technology is that it is difficult to maintain and preserve the proper 
conformation of proteins, especially when there are several membrane spanning domains. This 
can result in induction of a poor antibody response. One approach is to purify proteins from 
whole Salmonella rather than relying on recombinant proteins (Salazar-Gonzalez et al., 2004). 
As glycoconjugate vaccines primarily rely on the production of antibodies specific for the 
surface carbohydrate moieties, it may not be sufficient to efficiently deal with growing iNTS 
disease. The development of new live-attenuated, protein based, or GMMA (Generalized 
Modules for Membrane Antigens) based vaccines will surve to provide broader protection by 
activating Salmonella specific T cell responses (MacLennan et al., 2014). GMMA technology is 
used to deliver outer membrane proteins and surface polysaccharides in the correct orientation 
and confirmation to induce protective immunity. The use of GMMA has adjuvant activity by co-
delivering multiple PAMPs along with the target antigens (World Health Organization 2014). 
However, to date, vaccine development has been hindered due to a lack of understanding 
regarding specific antigenic epitopes of Salmonella, complications in protein purification, and 
manufacturing issues with respect to preservation of proper protein confirmation (MacLennan et 
al., 2014).  
This is a very brief discussion of Salmonella vaccines for animals. Out of all food animals, 
Salmonella vaccine industry is most developed for poultry (Table 1.3.2(c)), with the use of live 
attenuated, inactivated, and subunit vaccines (Desin et al., 2013). In poultry S. Gallinarum and S. 
Pullorum are the main causative agents of fowl typhoid fever and pullorum disease respectively. 
In addition, S. Enteritidis, S. Typhimurium, S. Heidelberg, and S. Kentucky cause asymptomatic 
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disease, and in rare cases systemic infection in mature chickens (Desin et al., 2013). Unlike in 
humans, vaccination of chickens does not lead to clearance of Salmonella, but a reduction of the 
level of Salmonella associated with the chicken upon infection (Desin et al., 2013). In addition to 
the previously discussed issues associated with live attenuated vaccines, one additional concern 
is that the live strain could survive for extended periods in chickens posing a health risk for 
humans (Tan et al., 1997). However, live attenuated strains are capable of horizontal transfer 
among birds, and therefore promising to be highly efficient vaccine antigens (Tan et al., 1997). 
Inactivated vaccines are made of killed whole Salmonella, and birds are immunized 
intramuscularly or subcutaneously and require a minimum of two doses (Barrow 2007; Gast 
2007). Although inactivated vaccines are capable of inducing strong antibody responses, they 
can be eliminated within a short time span by the host. In addition, these vaccines require 
adjuvants to confer optimal immune responses (Barrow 2007; Gast 2007). Salmonella subunit 
vaccines are mainly administered intramuscularly or subcutaneiously; oral administration 
requires the use of proper formulations to minimize antigen degradation in the intestine. 
Although, these vaccines do not pose many of the health risks associated with live attenuated 
vaccines, they are usually poorly immunogenic and require adjuvants. However, subunit 
vaccines for Salmonella are still at an early stage of development (Mutwiri et al., 2011). 
Currently there are many vaccine candidates being tested for use in poultry including nucleic 
acid, bacterial and viral vector based vaccines (Kaiser 2010). In addition, there are vaccines and 
vaccine candidates being tested for swine, cattle, and equines (Farzan and Friendship 2010; 
Singh 2009; Smith et al., 2015). 
 
Name Description Frequency of 
immunization 
Effect 
Nobilis® SG 9R Live-attenuated Twice (6 and14-16 
weeks) 
Protection (2.5% flocks were 
positive relative to 11.5% of control 
 
TAD Salmonella 
vac® E 
Live-attenuated Three doses (1 day, 6 
weeks, 16 weeks) 
Protection (12/28 liver, 6/28 
oviduct, 9/35 egg samples positive 
relative to control 22/30, 15/29, 
15/35 respectively) 
 
Megan® Vac 2 Live-attenuated Three doses (1 day, 2 
weeks, 5 weeks) 
Protection (38% cecal and 14% 
reproductive tract samples positive 
relative to control 68% and 52% 
respectively) 
 
Salenvac®  Inactivated Twice (1 day and 4 
weeks) 
 
Protection from shedding and 
reduction of colonization 
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AviPro®  
Salmonella vacT 
Live-attenuated Broiler: 1 dose, 
Layers/Breeders: 1 day, 
7 weeks, 16 weeks 
 
Limited persistence in internal 
organs and long lasting protecton 
from S. Typhimurium 
AviPro®  
Salmonella vacE 
Live-attenuated Three doses Short duration of shedding and 
protection from S. Enteritidis for 
laying hens 
Layermune SE® Inactivated Twice (5 and 9 weeks) Reduction of colonization in layers 
only 
 
Poulvac SE® Inactivated Twice (12 and 20 
weeks) 
Protection in day old chicks (7/25 
positive chicks relative to control 
25/25) 
 
Corymune® 4K 
and 7K 
 
Inactivated Twice (5 and 9 weeks) 
 
Minor effect on colonization 
 
Table 1.3.2(c): Commercial Salmonella vaccines for poultry. A brief summary of some widely used commercial 
live attenuated and inactivated vaccines in poultry against Salmonella colonization. Table adopted from Opinion of 
the scientific panel 2004 and Desin et al., 2013. 
 
Our group has previously discovered a novel surface associated polysaccharides termed O-
Antigen capsule in Non-Typhoidal Salmonella (NTS). The O-Antigen capsule is considered to 
be a common surface antigen, since the biosynthesis genes and cross-reactive material have been 
detected in all subgroups of Salmonella. In addition, the O-Antigen capsule genes were found to 
be expressed during in vivo infections in mice. Such an antigen would be a suitable candidate in 
developing a vaccine against Salmonella induced gastroenteritis. The goal of this research was to 
evaluate the potential of using O-Antigen capsule as a vaccine antigen to develop a traveler’s 
vaccine for gastroenteritis caused by NTS serovars.  
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2.0 HYPOTHESIS AND OBJECTIVES  
 
HYPOTHESES: 
 Deletion of the putative repressor of the O-Antigen capsule operon will boost the activity of the 
promoter and lead to more capsule production.  
 Immunization with purified S. Typhimurium O-Antigen capsule will generate an antibody 
response in rabbits and mice against the O-Antigen capsule. 
 
OBJECTIVES: 
1. To purify the O-Antigen capsule and to determine the best possible method to increase 
the yield of the capsule, while decreasing LPS contamination. 
2. To determine the appropriate dosage of O-Antigen capsule required to obtain the best 
possible immune response in mice immunized with purified S. Typhimurium O-Antigen 
capsule. 
3. To characterize the gene expression of the O-Antigen capsule operon. 
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3.0 MATERIALS AND METHODS  
 
3.1 Bacterial Strains and Growth Conditions 
 
Unless otherwise stated, the following were the standard conditions used in bacterial 
culture preparations. O/N cultures were grown in LB +/- antibiotic and incubated at 37oC. 
Antibiotic concentrations were as follows: Amp 100ug/mL (Amp100), Cm 10ug/mL (Cm10) or 
30ug/mL (Cm30), Tet 7ug/mL (Tet7), and Kan 50ug/mL (Kan50). For O-Antigen capsule 
purification, cells were grown on EPS agar and/or 1% Tryptone agar at 28oC-30oC for 5 days 
(detailed description in 3.4.1 “O-Antigen Capsule and X-factor Purification”). 
Luciferase assays were carried out in 1% Tryptone media with 50ug/mL Kan at 30oC. 
Bacterial strains used in this study are presented in Table 3.1. Some strains will be discussed in 
more detail in the 4.0 “Results” section.  
 
Strain Source 
 
E. coli DH10B Quandt J., and Hynes M.F. (1993). 
Gene. 127(1):15-21. 
H. Somni (HS25) Dr. Andrew Potter’s Lab, VIDO-
InterVac, University of 
Saskatchewan: Alberta field lot 
isolate from 1983 (lung isolate from 
a female cow with pneumonia) 
S. Enteritidis 27655-3b ΔbcsA White et al., (2003). Journal of 
Bacteriology. 185(18):5398-5407. 
S. Heidelberg S4825-1.1 phagetype19 Agri-Food Laboratories Branch, 
Food Safety and Animal Health 
Division, Alberta Agriculture and 
Rural Development (liver/spleen 
isolate from a chicken) 
S. Typhimurium ATCC 14028S WT American Type Culture Collection 
(ATCC), Manassas, VA, USA. 
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S. Typhimurium ATCC 14028S ΔyihQ Gibson et al., (2006). Journal of 
Bacteriology. 188(22):7722-7730. 
S. Typhimurium ATCC 14028S ΔbcsA This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihVW  This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihW  This Study 
S. Typhimurium ATCC 14028S WT pBR322-yihVW This Study 
S. Typhimurium ATCC 14028S WT pCS26-Pac-PyihU::lux This Study 
S. Typhimurium ATCC 14028S WT pCS26-Pac-PyihV::lux This Study 
S. Typhimurium ATCC 14028S WT pBR322-yihVW  
pCS26-Pac-PyihU::lux 
This Study 
S. Typhimurium ATCC 14028S WT pBR322-yihVW  
pCS26-Pac-PyihV::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA pBR322-yihVW This Study 
S. Typhimurium ATCC 14028S ΔbcsA pCS26-Pac-
PyihU::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA pCS26-Pac-
PyihV::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA pBR322-yihVW  
pCS26-Pac-PyihU::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA pBR322-yihVW  
pCS26-Pac-PyihV::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihVW pBR322-
yihVW 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihVW pCS26-Pac-
PyihU::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihVW pCS26-Pac-
PyihV::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihVW pBR322-
yihVW pCS26-Pac-PyihU::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihVW pBR322-
yihVW pCS26-Pac-PyihV::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihW pCS26-Pac-
PyihU::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihW pCS26-Pac-
PyihV::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihW pBR322-
yihVW pCS26-Pac-PyihU::lux 
This Study 
S. Typhimurium ATCC 14028S ΔbcsA ΔyihW pBR322-
yihVW pCS26-Pac-PyihV::lux 
This Study 
 
Table 3.1: Bacterial Strains used in this study. 
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3.2 Generating S. Typhimurium Mutants 
3.2.1 Cellulose Mutant ∆bcsA 
 
An in-frame deletion removing 1,998 bp in bcsA (encoding amino acids 165 to 828 in 
BcsA) was generated as previously described (Zogaj et al., 2001) with some modifications. 
Primer YHJ05 was modified to contain an EcoRI site instead of a BamHI site, and a new YHJ07 
primer (CCACTGCAGATTCGCGCCGCCTTCAGTAA [a PstI site is underlined]) was 
generated since S. Typhimurium bcsA contains a unique EcoRI site corresponding to amino acids 
828 to 829; primers YHJ06 and YHJ08 were used as described previously. Regions of DNA 
surrounding the bcsA gene were PCR-amplified from the S. Typhimmurium 14028S WT. The 
YHJ05+YHJ06 PCR product was digested with EcoRI and PstI to generate fragment #1 and the 
YHJ07+YHJ08 product was digested with PstI and HindIII to generate fragment #2. These 
fragments were sequentially cloned into pTZ18R, and then removed together by digesting with 
EcoRI and HindIII. The resulting product was ligated into pHSG415 and electroporated into S. 
Typhimurium 14028S (Figure 3.1.1). The allelic exchange procedure used is described in White 
et al., 2007. In potential bcsA mutant strains, the bcsA deletion was confirmed by a reduced 
product size upon PCR-amplification with Taq polymerase (New England Biolabs - NEB) and 
primers bcsAko1 (CGGCCCGTTACCTCATTCAG) and bcsAko2 
(TTCAGCACCGCTTTCGACGC); reaction conditions were as recommended by the 
manufacturer.  
 
3.2.2 Mutants S. Typhimurium ∆yihVW and S. Typhimurium ∆yihW  
 
PCR products containing the cat gene, which codes for  chloramphenicol resistance, and 50 
bp flanking regions corresponding to the beginning of yihV and the end of yihW were generated 
from pKD3 (Datsenko and Wanner, 2000) using Phusion polymerase (Fisher Scientific) and 
primers yihVWkoFOR (TTCGTGAAATTAAAATGAGCACATCGAAAATGCTTGAGGAA 
TGACCATGGGTGTAGGCTGGAGCTGCTTC) and yihVWkoREV (TTGGCCGGATAAAG 
CGCTGACGCGACCCTCCGGCGCAAGGGCGCTTGTCACCTCCTTAGTTCCTATTCCG): 
reaction conditions as recommended by the manufacturer. This PCR product was electroporated 
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into S. Typhimurium cells containing pKD46, which encodes the lambda-red recombinase gene 
products (γ,β,exo encoding Gam, Bet and Exo) required for chromosomal recombination. Gam 
inhibits RecBCD exonuclease V activity allowing Bet and Exo to gain access to DNA to 
promote recombination with cat (Datsenko and Wanner 2000). Recipient cells were plated on LB 
+ Cm10 agar and incubated O/N at 37
oC. Positive clones were re-streaked on to LB + Cm30 agar 
and incubated O/N at 37oC. Positive clones were checked by PCR for the replacement of yihVW 
with the CmR marker using Taq polymerase (NEB) and primers yihVWdetect1 (GCACATCGAA 
AATGCTTGAGGA) and yihVWdetect 2 (ATATCGCCTGCATCACAGCG); reaction 
conditions were as recommended by the manufacturer.  
Deletion of yihW was performed in the same manner as deletion of yihVW described above. 
The only difference was that pKD3 amplification was performed using Phusion polymerase and 
primers yihWkoF (TAATATGAGCAGTAGGAAGC TTTTAGAGGAATGCTCATGAGTGTA 
GGCTGGAGCTGCTTC) and yihVWkoREV; reaction conditions were as recommended by the 
manufacturer. Positive clones were confirmed as described above. 
P22 phage was used to move the mutation into a clean S. Typhimurium background. This 
avoids the possibility of any secondary mutations generated as part of the lambda-red 
recombination process. In this experiment P22 was used to move the yihVW::cat and yihW::cat 
mutations into S. Typhimurium ΔbcsA strain, following standard procedures (Maloy et al., 
1990). To generate final, unmarked mutant strains, the cat gene was removed from the 
chromosome using a helper plasmid (pCP20). The pCP20 encodes FLP recombinase which acts 
on FRT (FLP recognition target) sites flanking the cat gene. For this pCP20 was electroporated 
into S. Typhimurium ΔbcsA ΔyihVW::cat strain and grown O/N at 30oC on LB+ amp100 agar. 
One isolated colony was removed from the agar using a sterile loop and re-suspended in 
Phosphate Buffered Saline (PBS). Serial dilutions were performed, and 100 L of the 10-5 and 
10-6 dilutions were inoculated onto LB agar and incubated at 42oC O/N. This step cures the cells 
of pCP20. Loss of the cat gene from the chromosome and the pCP20 plasmid was confirmed by 
patch plating of ~30 colonies onto LB agar or LB agar supplemented with Cm30 or Amp100. 
Colonies that grew on LB agar only were selected for further screening: 1) drop in PCR product 
size using Taq polymerase (NEB) and primers yihVWdetect1 and yihVWdetect2 and 2) DNA 
sequencing of the amplified PCR products.  
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Figure 3.1.1: Creation of cellulose mutant (ΔbcsA) S. Typhimurium strain. (A) Map of pHSG415 containing the 
antibiotic resistance markers. (B) Schematic representation of allelic replacement procedure. (C) Different PCR 
reactions used to generate and detect the mutation; the deleted region (blue), the gene of interest (red), PCR primers 
for detecting the deletion (black arrow), and PCR primers used for making the deletion (grey arrows). Figure 
adopted with modifications from White et al., 2007, reproduced with kind permission from Canadian journal of 
Microbiology. 
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3.3 Cloning 
3.3.1 yihVW Cloning 
 
The DNA region containing yihVW (1918bp) was PCR amplified from S. Typhimurium 
14028S genome using Phusion polymerase (Fisher Scientific) and primers yihVWFOR 
(CGCGCTGCAGCTGTTTGTGATCGTATTTGTAATTTAT) and yihVWREV (GATCGACGT 
CGCATCACAGCGCCGTTTTATTG); reaction conditions as recommended by the 
manufacturer. The resulting PCR product was digested with AatII and PstI and ligated into 
AatII/PstI cut pBR322 prior to electroporation into S. Typhimurium WT, S. Typhimurium ΔbcsA 
and S. Typhimurium ΔbcsA ΔyihVW strains. Positive clones were selected by growing on LB + 
Tet7 agar. The pBR322-yihVW ligation was confirmed by sequencing using primers yihVWseqF 
(GATCTTGCCGGGAAGCTAGAGTAAG) and yihVWseqR (GATCTTCTTGAAGACGAAAG 
GGCCT). 
 
3.3.2 O-Antigen Capsule Operon Cloning  
 
The 9650bp yihUTSRQPO-yshA operon was PCR-amplified from the S. Typhimurium 
14028S genome using Phusion polymerase (Fisher Scientific) and primers CloneFOR (GACTA 
GTACTTCCTCAAGCATTTTCGATGTGC) and CloneREV (GACTAGTACTACCCGCTGTG 
ATGCTGATTC); reaction conditions as recommended by the manufacturer. Since the region of 
DNA was so large, there were no unique restriction sites available for cloning purposes, thus 
blunt-ended ligations were performed.  In one cloning strategy, yihUTSRQPO-yshA PCR product 
and pACYC184 were both digested with ScaI and ligated together. In another strategy, 
yihUTSRQPO-yshA PCR product was digested with ScaI while pBR322 was digested with ScaI 
and ZraI. The yihUTSRQPO-yshA cloning was also tried by only digesting pACYC184 with 
ScaI.  
Once it was determined that yshA was not part of the O-Antigen capsule operon (RNA-seq; KD 
MacKenzie, Y Wang and AP White, unpublished data), a second blunt end cloning was 
performed. PCR amplified yihUTSRQPO (8890bp) from S. Typhimurium 14028S genome using 
Phusion polymerase and primers CloneFOR and CloneREV2 (GACTAGTACTTTCAAATATA 
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GGGAAGCCGC); reaction conditions were as recommended by the manufacturer. This PCR 
product was naturally blunt ended. Then the yihUTSRQPO PCR product and pACYC184, which 
was digested with EcoRV, were ligated together.  
 
3.4 Purification 
3.4.1 O-Antigen Capsule and X-factor Purification 
 
An O-Antigen capsule purification method was adopted from Gibson et al., 2006 with 
modifications. 300uL of S. Typhimurium O/N cultures were spread on agar plates (d=140mm) 
containing either 1% Tryptone media or EPS (extracellular polysaccharide) media (pH 8.23) that 
contain 0.05% yeast extract, 1% D-glucose, 1.5% agar, 10mM sodium phosphate dibasic 
anhydrous, 0.1% ammonium chloride, and 0.3% potassium phosphate monobasic. Cells were 
incubated at 28oC-30oC for five days, following which cells were scraped off agar surfaces, re-
suspended in 1%, 5% or 10% phenol, and gently mixed at room temperature for 1h to lyse the 
cells. This was followed by centrifugation (16,000xg, 4h, 4oC) to separate polysaccharides from 
other cell material. Polysaccharides were precipitated by mixing the supernatant with four 
volumes of ice cold acetone while continuously stirring. The pellet containing cellular debris was 
discarded. Precipitated material was stored overnight at -20oC to allow for any further 
precipitation. The precipitate in the acetone/supernatant solution was collected by centrifugation 
(6000xg, 20min, 4oC), air dried, dissolved in ddH2O and dialysed (10K MWCO – SnakeSkin 
Dialysis Tubing, Thermo Scientific) against dH2O for 48h at 4
oC. This solution was lyophilized 
(Freeze-dried) and the dry weight of the polysaccharide material was measured prior to further 
purification using anion and size exclusion chromatography.  
The fractions eluted at the end of anion exchange chromatography of O-Antigen capsule 
contained the X-factor. Therefore, at this stage, both the X-factor and the O-Antigen capsule 
were extracted together from the cells. 
Anion Exchange Chromatography 
The lyophilized polysaccharides were dissolved in 95mL of buffer A (15mM NaOAc, 
0.05% Triton X-100 pH 5.5) and 0.01% sodium azide, and heated at 37oC for 10-15min. The 
sample (100mL of diluted curde sample, pH 5.53, electrical conductivity 540uS/cm) was filtered 
through a 0.22µm filter prior to loading onto the Q Sepharose FF xk50/11.5 column. The flow 
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rate was 8.5mL/min, and the fraction size was 20mL. Then the column was washed with 2 
column volumes of 100% buffer A followed by 1.6 column volumes of 7% buffer B (1.5M 
NaOAc, 0.05% Triton X-100, pH 5.5). Next, buffer B concentration was increased sequentially 
to 17% (1.25 column volumes), 50% (1.25 column volumes) and 100% (1.5 column volumes) 
prior to flushing the resin with 2 column volumes of buffer D (2M NaCl). The cleanest fraction 
of the O-Antigen capsule eluted with 17% buffer B, whereas less pure fractions eluted with 7% 
and 17% buffer B. Western blotting confirmed which peaks or fractions corresponded to the O-
Antigen capsule after anion exchange chromatography. The capsule fractions that eluted with 7% 
buffer B were run separately on size exclusion resin. Final fractions, eluted in 2M NaCl, 
contained the X-factor, which was collected and run separately on size exclusion 
chromatography. 
Size Exclusion Chromatography 
Fractions from anion exchange were pooled together according to purity and concentrated 
(50K MWCO - centrifugal filters, Millipore). These fractions (2.0-7.5mL) were filtered through 
a 0.22µm syringe tip filter prior to loading on to the Superdex S300 prep grade xk26/95 column. 
The flow rate was 0.45mL/min and the fraction size was 7.5mL. Although the O-Antigen capsule 
was expected to elute in 1 column volume (185-190mL of retention volume), the sample was 
eluted with 3 column volumes. 
Fractions containing the O-Antigen capsule were concentrated either with a Millipore-
Amicon Ultra-15 Centrifugal Filter Device or using a vacuum concentrator. Then these fractions 
were mixed with SDS sample buffer, boiled for 5min at 95oC, centrifuged at 3800xg for 5min 
and run on either a 7.5% resolving SDS-PAGE gel alone or on a 12% resolving and 5% stacking 
SDS-PAGE gel (Molecular weight standard - Precision Plus protein dual colour standard, Bio-
Rad.) Following this, samples were transferred to nitrocellulose membrane using a Trans-Blot 
SD semi-dry transfer cell (Bio-Rad Laboratories) in buffer recommended by the manufacturer. 
After transfer, the membrane was blocked in 5% skim milk either for 1h at 37oC or overnight at 
4oC. Following this the membrane was incubated for 1h in primary antibody: rabbit polyclonal 
immune serum specific for S. Typhimurium (or S. Enteritidis) O-antigen capsule (1:1000), or 
rabbit polyclonal immune serum specific for S. Typhimurium (or S. Enteritidis) X-factor 
(1:1000). Initial screening was carried out using rabbit serum specific for S. Enteritidis O-antigen 
capsule (obtained from Deanna Gibson, UBC-Okanagan). Each step was followed by washing 
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with1% TBST (Tris-Buffered Saline with 1% Tween 20). The secondary antibody (alkaline 
phosphatase conjugated goat anti-rabbit serum) was used at 1:2000 dilution. Immunoreactive 
material was visualized by incubating in BCIP (5-bromo-4-chloro-3-indolylphosphate) and NBT 
(4-nitroblue tetrazolium chloride) solution. Dot blots were performed similar to Western-blots. 
However, instead of running the sample on a SDS-PAGE gel, it was directly pipetted on to the 
Nitrocellulose membrane and allowed to air dry. Then the membrane was developed in the same 
manner as a Western blot. 
 
3.4.2 Endotoxin Removal 
 
Twenty grams of Triton X-114 (Sigma-Aldrich) and 16mg of 2,6-Di-tert-butyl-4-
methylphenol (Aldrich) were mixed and dissolved at 4oC, and this mixture was buffer exchanged 
with 10mM Tris (pH7.4) and 150mM NaCl (Bordier 1981). This solution was poured into a 
separator funnel and incubated at 30oC until the mixture separated into a large aqueous phase and 
a small Triton-enriched phase. The smaller phase was buffer-exchanged two more times with an 
equal volume of Tris-NaCl solution and incubated at 30oC. The resulting 11% Triton X-114 
solution was stored at room temperature. Following size exclusion chromatography, O-Antigen 
capsule-containing fractions were combined together and dialyzed in dH2O for 48h at 4
oC (10K 
MWCO – SnakeSkin Dialysis Tubing, Thermo Scientific). The dialyzed material was 
lyophilized and the resulting powder was dissolved in dH2O at a concentration of 0.5mg/mL. An 
aliquot of this solution was saved as a “pre-LPS removal” control for use in subsequent 
experiments. Using the 11% Triton X-114 stock solution (described above), a 1% Triton X-114 
solution was prepared and this was mixed with 0.5mg/mL O-Antigen capsule solution. This 
mixture was initially cloudy, but turned clear (after stirring for 30min on ice or O/N at 4oC). 
After this step, the solution was dispensed in to 25mL centrifuge tubes and incubated for 30min 
at 37oC (after which the solution turned cloudy). The tubes were centrifuged for 30min at 1200xg 
at 25oC, and the solution separated in to two phases. The upper phase containing the O-Antigen 
capsule was mixed with 2% Triton X-114 and extracted as per 1% Triton. The lower LPS 
containing phase was stored separately at 4oC. The 2% Triton step was repeated for a total of 
three times. Centrifugation speed and time for each step was adjusted to obtain the best 
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separation of the two phases. This procedure was adopted with modifications from Adam et al., 
1995.  
To remove Triton X-114 from the O-Antigen capsule-containing solution, Triton-capsule 
solution was mixed with three volumes of a 2-methanol:1-chloroform solution and poured in to a 
separator funnel. Once the solution separated into two phases (at room temperature), the Triton 
X-containing lower phase was eluted. The O-Antigen capsule-containing upper phase was mixed 
again with the methanol-chloroform solution; this procedure was repeated two additional times. 
Any remaining methanol-chloroform was removed from the sample using a water aspirator. 
Following this, the sample was dialysed for 48h in dH2O at 4
oC, lyophilized, and the resulting 
powder (shiny, brown powder) was weighed and recorded as the yield of the final-purified 
capsule. Purified capsule was resolved by SDS-PAGE and tested on Western blots for the 
presence of O-Antigen capsule and LPS. Capsule was detected using rabbit polyclonal immune 
serum specific for S. Typhimurium (or S. Enteritidis) O-Antigen capsule (1:1000) and LPS was 
detected using mouse monoclonal antibody specific for S. Typhimurium LPS [1E6] (Abcam: 
ab65922). Alternatively, the presence/absence of LPS was verified using silver staining as 
described by Kropinski et al., 1986.  
 The amount of LPS associated with the O-Antigen capsule was quantified using the 
Limulus Amebocyte Lysate (LAL) assay (QCL-1000, Lonza, Walkersville, MD, USA), 
according to the manufacturer’s guidelines. In this assay, the LPS quantity of crude capsule 
(prior to LPS extraction) was compared to that of the purified capsule (after LPS extraction). 
 
3.5 Immune Serum Generation  
 
Four New Zealand white rabbits were immunized subcutaneously (s.c.) with a specific 
concentration of purified (LPS removed) O-Antigen capsule or X-factor.  Group A received S. 
Typhimurium X-factor, Group B received S. Enteritidis X-factor, Group C received S. 
Typhimurium O-Antigen capsule, and Group D received S. Enteritidis O-Antigen capsule. Each 
antigen was dissolved in PBS (phosphate buffered saline) and mixed with 30% Emulsigen, 
which was used as an adjuvant. 
 Prior to primary immunization, 1-2mL of blood was collected from each rabbit as a pre-
immunization control. The immunization doses and schedule were as follows: Day0, primary 
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immunization with 100ug O-Antigen capsule or X-factor; Day21, immunization with 50ug O-
Antigen capsule or 100ug X-factor; Day42, immunization with 50ug O-Antigen capsule or X-
factor.  After each immunization 1-2mL of blood was collected from each rabbit and used to 
determine the antibody titer (ELISA). Animals were euthanized on Day 52 and blood samples 
were collected into Serum Separator Tubes. 
The blood samples were centrifuged at 3700xg for 10min at 4oC, which separated the 
blood in to three phases: the lowest phase containing cell material, the middle phase containing 
protein and the upper phase containing serum. Serum was collected and stored at -20oC. For 
ELISAs, Immulon II Immunoassay 96 well plates (Thermo Scientific) were coated with 
0.5ug/mL O-Antigen capsule in coating buffer (1.32g Na2CO3 and 3.16g NaHCO3 in 1L dH2O, 
pH 9.6) and incubated O/N at 37oC. The plates were washed with 0.5% TBST (Tris-Buffered 
Saline with 0.5% Tween 20) prior to pipetting 5% skim milk into each well and incubating for 3h 
at 37oC. Serially diluted primary antibody (rabbit serum) was added to each well and incubated 
for 1h at room temperature. Each step was followed by washing with1% TBST (Tris-Buffered 
Saline with 1% Tween 20). The secondary antibody (alkaline phosphatase conjugated goat anti-
rabbit serum) was used at 1:2000 dilution. The reaction was developed with PNPP (p-nitrophenyl 
phosphate di(tris) salt crystalline – Sigma N3254) substrate (10uL PNPP stock [1g PNPP in 
10mL substrate buffer] and 1mL substrate buffer [10mL Diethanolamin – Sigma D8885 and 
1mL 500mM MgCl2 in 1L dH2O, pH 9,8]). The reaction was stopped with 0.3M EDTA (pH 8.0) 
and absorbance measured at 490nm reference wavelength using Spectramax Plus 384 Microplate 
Reader (Molecular Devices, Sunnyvale CA). 
 
3.6 O-Antigen Capsule Dosage Trial 
 
Seven groups of ~8 week old female BALB/c mice (n=6) were immunized twice 
intramuscularly as follows: Group A: 5ug O-Antigen capsule + adjuvant, Group B: 5ug O-
Antigen capsule, Group C: 25ug O-Antigen capsule + adjuvant, Group D: 25ug O-Antigen 
capsule, Group E: 50ug O-Antigen capsule + adjuvant, Group F: 50ug O-Antigen capsule, and 
Group G: 50ug O-Antigen capsule + 30% Emulsigen (positive control group) The “triple-
combo” adjuvant was developed at VIDO-InterVac and contained CPG ODN, Poly I:C (a host 
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defense peptide), and polyphosphazeen at a 1:1:2 ratio. Mice from different groups were co-
housed in a formally randomized manner and we were blinded as to the group designations until 
the final data had been collected. All the mice in the positive control group were placed in one 
cage since Animal Care can only put six mice in a cage and there were seven groups. 
Mice were immunized on days 0, and 28 with the antigens as described above, while blood 
samples (50uL) were collected on days 0, 21, and 42. Mice were euthanized on Day 52 and all 
the blood was collected. Blood samples were separated by centrifugation, as described in 3.5 
“Immune Serum Generation” and the serum was stored at -20oC until ELISA was performed. 
ELISAs were performed as described in 3.5 “Immune Serum Generation”. For ELISAs, 
Immulon II Immunoassay 96 well plates (Thermo Scientific) were coated with 1.25uL/well O-
Antigen capsule in coating buffer. The yield of O-Antigen capsule was quite low after 
purification, and it was not possible to determine the weight. Thus with an antigen titration 
ELISA it was determined that the optimal amount of O-Antigen capsule for screening was at 
1.25uL/well. The mouse serum (pre-bleed, post 1st immunization serum, and post 2nd 
immunization serum) was used at 1:50 and 1:200 dilutions. The secondary antibody (alkaline 
phosphatase conjugated goat anti-mouse serum) was used at a 1:2000 dilution. 
 
3.7 Luciferase Assays 
 
Expression of the divergent operons (yihUTSRQPO and yihVW) coding for O-Antigen 
capsule biosynthesis was measured using promoter-luciferase fusions. DNA regions containing 
Promoter yihUTSRQPO (PyihUTSRQPO) and Promoter yihVW (PyihVW) were cloned into 
pCS26-Pac plasmid containing luxCDABE of Photorhabdus luminescens (Bjarnason et al., 2003 
and Gibson et al., 2006). The resulting plasmids were transformed into each Salmonella strain; 
promoter activation resulted in expression of luxCDABE which was measured through light 
production. Different intensities of promoter activity were reflected in the light output. To 
perform luciferase assays, O/N cultures of each reporter strain were diluted 1:600 into a final 
volume of 150uL/well containing the desired growth medium (EPS media, EPS media with 2,2’-
dipyridyl, 1% Tryptone, or LB +/- sugars) in 96-well clear-bottom, black plates (9520 Costar; 
Corning Inc.). The optical density (at 590nm) and light production (counts per second) was 
measured every 30min for 48h using a Wallac-Victor X3 multi-label plate reader  (Perkin-Elmer 
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Life Sciences, Boston MA). The strain containing pCS26-Pac with either PyihUTSRQPO or 
PyihVW was also used in assessing the light production by individual colonies. For this, each 
strain was streaked for single colonies on LB agar + Kan50 and incubated O/N at 37
oC. Light 
production by individual colonies was measured using an IVIS Lumina II (Perkin-Elmer Life 
Sciences).  
 
3.8 Capsule Staining and Microscopic Imaging 
 
Capsule staining was performed using Maneval’s stain, where 10uL of Congo red dye was 
placed on a clean slide and mixed with a small amount of a colony from the desired strain (A 
single colony was touched with a pipette tip and the tip was swirled in the Congo red dye on the 
slide). The slide was allowed to air dry for ~1h. Following this, the slide was placed on a staining 
tray and flooded with Maneval’s solution (Merlan Scientific Ltd. Mississauga, ON, Canada) and 
incubated for 2min. Then the excess stain was washed off with dH2O and the slide was allowed 
to air dry for ~1h prior to visualization with a light microscope (63X objective lens). 
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4.0 RESULTS 
 
4.1 Purifications 
4.1.1 Crude Capsule Purification 
 
The purification of O-Antigen capsule was difficult in the presence of cellulose (Gibson et 
al., 2006), resulting in lower yields than what had been previously reported by others (Snyder et 
al., 2006). This was because cellulose non-specifically traps all polysaccharides, including O-
Antigen Capsule, in the extracellular matrix. In Salmonellae, bcsA codes for the catalytic subunit 
of cellulose synthase (Solano et al., 2002; Barak et al., 2007). To allow for more efficient capsule 
purification in the absence of cellulose, a deficient strain (S. Typhimurium ∆bcsA) was generated 
with allelic replacement. The final confirmation of the bcsA deletion was done by analyzing the 
colony morphology of potential mutant strains. While WT colonies were characterized by a dry, 
rough texture, undefined edges, and a pattern on top, the bcsA mutant strain colonies were 
smooth, shiny, and had round edges (Figure 4.1.1(a)).  
 
A B
 
Figure 4.1.1(a): Phenotypes of WT and bcsA mutant S. Typhimurium strains. (A) S. Typhimurium WT. (B) S. 
Typhimurium ∆bcsA. Both strains were grown on 100ug/mL Congo red + 1% Trypton agar at 28oC for 5 days. 
 
Initially, the O-Antigen capsule was purified from both S. Typhimurium ∆bcsA and S. 
Enteritidis ∆bcsA strains, but for subsequent experiments only the S. Typhimurium ∆bcsA strain 
was used. The crude polysaccharides were white, powdery material that had the texture of cotton 
(Figure 4.1.1(b)). Following crude purification of the polysaccharides, samples were further 
purified using anion exchange followed by size exclusion chromatography. Fractions from size 
exclusion chromatography were tested by Western blotting to identify O-Antigen capsule-
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containing fractions (Figure 4.1.1(c)). The size exclusion chromatograph contained two peaks, 
where the first peak was always associated with O-Antigen capsule and the composition of the 
second peak was unknown. In the absence of a stacking gel, crude polysaccharides were smeared 
on Western blots from top to bottom of the lane. Laddering seen on the bottom of lanes were 
associated with low-molecular weight LPS. Upon confirmation on Western blots, O-Antigen 
capsule-positive fractions were pooled together and used in subsequent purifications.  
 
 
Figure 4.1.1(b): Physical appearance of crudely purified polysaccharides. Crude polysaccharides were white, 
cotton like material soluble in water upon vigorous stirring or with gentle heating.  
 
 
A B
 
 
Figure 4.1.1(c): Crude O-Antigen capsule detection following chromatography. (A) Size exclusion 
chromatogram.  (B) Western blot showing crudely purified O-Antigen capsule fractions from S. Typhimurium 
ΔbcsA following size exclusion chromatography detected using rabbit polyclonal immune serum specific for S. 
Typhimurium O-Antigen capsule (1:1000).  
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For developing an effective vaccine against NTS it is important to ensure that there will be 
immune memory and cross-protection between different serovars. Therefore, it was important to 
determine early on if cross recognition of O-Antigen capsule from different serovars was 
possible for serum generated against the capsule of a given serovar. Prior to specific serum 
generation (discussed in 4.2 “Animal Trials”), S. Typhimurium O-Antigen capsule was 
visualized on Western blots using the serum specific for S. Enteritidis O-Antigen capsule 
(obtained from Deanna Gibson, UBC-Okanagan) (Figure 4.1.1(d)). In addition, crude 
polysaccharides were extracted from Salmonella serovar Heidelberg; a previously 
uncharacterized serovar with respect to O-Antigen capsule production. S. Heidelberg O-Antigen 
capsule was further purified using anion exchange (Figure 4.1.1(e)-A) and size exclusion 
chromatograms and the resulting fractions were tested on dot blots. Rabbit polyclonal serum 
specific for S. Enteritidis O-Antigen capsule was used to detect the presence of capsule in S. 
Heidelberg samples (Figure 4.1.1(e)-B). O-Antigen capsule from S. Typhimurium and S. 
Enteritidis were used as positive controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.1(d): Cross recognition of S. Typhimurium O-Antigen capsule by serum specific for S. Enteritidis 
capsule: Western blot showing the crudely purified O-Antigen capsule following size exclusion chromatography 
detected using rabbit polyclonal immune serum specific for S. Enteritidis O-Antigen capsule (1:1000) – serum 
obtained from Deanna Gibson, UBC-Okanagan 
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Figure 4.1.1(e): Cross recognition of S. Heidelberg O-Antigen capsule by serum specific for S. Enteritidis capsule: 
(A) Anion exchange chromatogram and peaks corresponding to the O-Antigen capsule. (B) Dot blot showing the crudely 
purified S. Heidelberg O-Antigen capsule following size exclusion chromatography detected using rabbit polyclonal 
immune serum specific for S. Enteritidis O-Antigen capsule (1:1000) – serum obtained from Deanna Gibson, UBC-
Okanagan. S. Enteritidis (SE) and S. Typhimurium (ST) O-Antigen capsules are used as controls. 
 
4.1.2 O-Antigen Capsule Purification from Additional Mutant Strains of S. Typhimurium  
 
Through gene expression studies (discussed in 4.3 “Gene Expression Studies”) it was 
observed that the promoter for the O-Antigen capsule operon (PyihUTSRQPO) mediated elevated 
expression in the absence of the repressor YihW. Thus, the standard purification protocol using 
S. Typhimurium ΔbcsA strain grown on EPS agar was changed to include the S. Typhimurium 
ΔbcsA ΔyihVW strain grown on 1% Tryptone agar. However, during the first attempt, it was 
difficult to obtain any crude capsule from this strain. As it was not explicitly clear whether this 
was due to an inability to produce capsule by the S. Typhimurium ΔbcsA ΔyihVW strain or that 
the cell lysis method was inadequate, given that the absence of YihVW may have altered the cell 
surface dynamics, it was considered best to increase the phenol concentration during cell lysis. 
Thus, a range of phenol concentrations were tested from 2%, 5% and 10%, and 10% phenol was 
considered best in replacing the existing 1% phenol in lysing cells. 
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As the deletion of yihVW resulted in S. Typhimurium ΔbcsA ΔyihVW not producing any 
crude polysaccharides, it was considered that maybe YihVW were necessary in activating or 
positively regulating the O-antigen capsule operon. Thus, yihVW were cloned in to pBR322 and 
introduced in to S. Typhimurium ΔbcsA and S. Typhimurium ΔbcsA ΔyihVW strains. However, 
during purifications, the yield of crude polysaccharides from pBR322-yihVW containing strain 
was half as much as that from the S. Typhimurium ΔbcsA strain. As a result it was unclear 
whether YihVW were acting as activators or repressors of the O-Antigen capsule operon. One 
explanation was that maybe YihV (a kinase) was involved in capsule production, and deletion of 
yihV interfered with this process. Therefore, a yihW deletion strain was constructed to determine 
whether the absence of YihW and the presence of YihV may lead to an increase in capsule 
production. During purification S. Typhimurium ΔbcsA ΔyihVW produced 0.6x and S. 
Typhimurium ΔbcsA ΔyihW produced 2.5x crude polysaccharides compared to S. Typhimurium 
ΔbcsA strain. Therefore YihV may have a regulatory role in promoting capsule production.  
Crude polysaccharides from all three strains: S. Typhimurium ΔbcsA, S. Typhimurium 
ΔbcsA ΔyihVW and S. Typhimurium ΔbcsA ΔyihW, were further purified through anion 
exchange and size exclusion chromatography and resulting O-Antigen capsule fractions were 
visualized on a Western blot (Figure 4.1.2). Capsules from all three strains were detected using 
rabbit polyclonal serum specific for S. Typhimurium O-Antigen capsule. Although S. 
Typhimurium ΔbcsA ΔyihW produced more crude polysaccharides, capsule material from all 
three strains visually appeared the same and had bands of same thickness on the Western blot. 
The O-Antigen capsule was associated with the top of the resolving gel while the lower 
molecular weight LPS bands appeared below the capsule. 
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Figure 4.1.2: Comparison of Crude O-Antigen capsule between three different strains. Crudely purified O-
Antigen capsule samples from S. Typhimurium ΔbcsA, S. Typhimurium ΔbcsA ΔyihVW, and S. Typhimurium 
ΔbcsA ΔyihW following size exclusion chromatography were detected using rabbit polyclonal immune serum 
specific for S. Typhimurium O-Antigen capsule (1:1000).  
 
4.1.3 Endotoxin Removal 
 
Size exclusion chromatography separates molecules based on their size. Following size 
exclusion chromatography, LPS, being a lower molecular weight molecule, was expected to be 
separated from higher molecular weight O-Antigen capsule. However, in Western blots 
conducted following chromatography, there was a distinct LPS banding pattern at the bottom of 
each lane containing the O-Antigen capsule samples (Figure 4.1.3(a) left lane). To specifically 
test for the presence of LPS, crude O-Antigen capsule samples were separated on a SDS-PAGE 
gel and either transferred to a membrane and detected using mouse monoclonal serum specific 
for S. Typhimurium LPS [1E6] (Abcam: ab65922) (Figure 4.1.3(a) right lane) or silver stained; a 
procedure highly sensitive to bacterial LPS in polyacrylamide gels. Both of these methods were 
able to confirm that LPS was associated with crudely purified O-Antigen capsule even after 
chromatography. 
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The presence of LPS in a vaccine is not desired as LPS is pyrogenic, can lead to 
inflammation, endotoxic shock and even death. For purposes of this vaccine, the concern is that 
if LPS is present in the vaccine, the immune response mounted will be against LPS and not the 
O-Antigen capsule. Immune response to LPS is known to be strain specific and will not provide 
cross-protection. In this case, the vaccine will not be effective. As such, there was a pressing 
need to remove LPS from O-Antigen capsule.  
 
Figure 4.1.3(a): Detection of LPS associated with crude O-Antigen capsule. O-Antigen capsule and LPS were 
visualized using: left lane - rabbit polyclonal serum specific for S. Typhimurium O-Antigen capsule, right lane - 
mouse monoclonal serum specific for S. Typhimurium LPS [1E6] (Abcam: ab65922). 
 
LPS and O-Antigen capsule are both polysaccharides associated with the ECM. However, 
there are unique distinguishing features between the two polysaccharides. For example, in S. 
Typhimurium O-Antigen capsule, both abequose and galactose residues are partially substituted 
with a polymeric glucose side chain. However in LPS only galactose residue is substituted with a 
glucose side chain (Figure 4.1.3(b)). In addition, O-Antigen capsule has over 2300 repeat units 
while LPS has only 20-30 repeat units. Also, LPS is attached to the cell surface through the lipid-
A core region, while the O-Antigen capsule is covalently attached to an uncharacterized 
glycolipid anchor (Snyder et al., 2006 and Gibson et al., 2006). Furthermore, LPS has an overall 
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lower net charge than O-Antigen capsule and can be separated by anion exchange 
chromatography. 
 
 
 
Figure 4.1.3(b): Schematic representing the linear configuration of the S. Typhimurium O-Antigen capsule 
and LPS. Both abequose and galactose residuces on the O-Antigen capsule are partially substituted with a glucose 
side chain, while only galactose in LPS has this modification. 
 
Following chromatography O-Antigen capsule-containing fractions (confirmed using 
Western blots) were pooled together and mixed with Triton X-114, which acts as a detergent and 
dissociated LPS molecules from O-Antigen capsule. This procedure was adapted from Adam et 
al., 1995. At room temperature Triton X-114 solution separated into two phases where the 
dissociated LPS molecules were associated with the micellar rich lower phase, while the O-
Antigen capsule was associated with the micellar poor upper phase (Figure 4.1.3(c)) (Wang and 
Coppel 2002). The original protocol was to remove LPS by performing a series of seven Triton 
X-114 extractions (Adam et al., 1995). However, it was found that four Triton X-114 extractions 
of the O-Antigen capsule sample removed a significant amount of LPS and left a detectable 
amount of O-Antigen capsule. In capsule purification, the additional incubation steps with Triton 
X-114 reduced the amount of LPS, but also decreased the final concentration of O-Antigen 
capsule. Upon removal of Triton X-114 from the sample with a methanol-chloroform mixture, 
the presence of the O-Antigen capsule and reduction of LPS was confirmed with Western blots 
(Figure 4.1.3(d)). O-Antigen capsule was faintly visible when using serum specific for S. 
Typhimurium O-Antigen capsule, as most of the capsule had been lost during the purification. 
However, LPS was not present at a detectable level in the purified capsule sample. 
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Figure 4.1.3(c): Schematic representation of Triton X-114 phase separation. Triton X-114 separated at room 
temperature in to a micellar poor upper phase containing O-Antigen capsule and a micellar rich lower phase 
containing LPS. Figure extracted from Magalhaes et al., 2007, reproduced with kind permission from Journal of 
Pharmacy and Pharmaceutical sciences. 
 
The amount of remaining LPS associated with O-Antigen capsule was quantified with 
Limulus Ameobocyte Lysate (LAL) assays (www.lonza.com). LAL is a extremely sensitive 
assay and thus the results were considered highly accurate. In one purification round, crudely 
purified S. Typhimurium O-Antigen capsule, prior to LPS removal, had an LAL value of 
1.84*108 EU/mg. Upon LPS removal with Triton X-114, the LAL value was reduced to 2.5*103 
EU/mg. Although the LAL value was not zero, this was a significant reduction in the 
concentration of LPS compared to that of the crude material, and was within the biologically safe 
limit to administer to mice. According to Beutler et al., 1985, LD50 was achieved when 4.55*10
6 
EU/ml of edotoxin was administered to a 20g mouse. Copeland et al., 2005 demonstrated that 
administration of 1.0*103EU/mL of endotoxin to a 20g mouse was non-lethal. The final purified 
O-Antigen capsule had 2.5*103 EU/ml of edotoxin, and the highest dose of antigen administered 
to mice was 50μg. Therefore in 50μg there was 1.25*102EU of LPS, which was within the 
biologically acceptable limit to administer to mice. 
In previous purifications it was determined that it was not possible to remove all the LPS 
without greatly reducing the O-Antigen capsule concentration as well. Thus, at this level, there 
was sufficient LPS removed for the vaccine to be biologically safe and sufficient O-Antigen 
capsule remaining to mount a protective immune response.  Throughout the purification process, 
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the concentration of O-Antigen capsule had been greatly reduced that at the end only a small 
fraction of the starting material was still present (Figure 4.1.3(e) and Table 4.1.1).  
 
 
Figure 4.1.3(d): Purified O-Antigen capsule detected on western blots. Triton X-114 treated O-Antigen capsule 
tested on Western blots for the presence of capsule and reduction of LPS. Purified capsule treated four times with 
Triton X-114. Crude capsule prior to LPS removal was used as a control. Detected using: (A) rabbit polyclonal 
serum specific for S. Typhimurium O-Antigen capsule, (B) mouse monoclonal serum specific for S. Typhimurium 
LPS [1E6] (Abcam: ab65922). 
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Figure 4.1.3(e): The yield of O-Antigen capsule throughout the purification process. 
 
4.1.4 Influence of Growth Media on Capsule Yield 
 
In order to optimize O-Antigen capsule production, many different growth conditions 
were assessed both for PyihUTSRQPO activity and the yield of crude polysaccharides. It was 
observed that growth of S. Typhimurium ΔbcsA ΔyihVW on Tryptone agar produces ~2.3 
times more crude polysaccharide compared to growth on EPS agar. However, this increase in 
yield did not reflect the100-fold increase in PyihUTSRQPO activity observed in luciferase 
assays (discussed in 4.3 “Gene Expression Studies”). Thus, initially the low yield was 
considered to be a result of improper cell lysis. However, further reasoning indicated that even 
if the cells were not being lysed properly, O-Antigen capsule had to be produced, as 
PyihUTSRQPO was highly expressed under the same growth conditions. Using Western blots, 
the presence of the capsule was tested in the following samples: cells scraped off agar surfaces 
(cells), the cell debris pellet following phenol lysis and centrifugation (pellet), the 
polysaccharide precipitate following acetone treatment (precipitate), and the supernatant of 
this precipitate (supernatant). Both the cells and the pellet were normalized to 1.0 OD600, 
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(OD600 is optical density or absorbance of a samples when the wavelength is at 600nm) and the 
precipitate and supernatant were lyophilized and used at 0.5mg/mL.  
The majority of O-Antigen capsule was present in the precipitate sample with high 
molecular weight material corresponding to the O-Antigen capsule (Figure 4.1.4(a)). Cells and 
the pellet had low levels of capsule, while the supernatant did not appear to contain capsule. 
This assay was repeated with identical results for S. Typhimurium ΔbcsA ΔyihVW pBR322-
ΔyihVW grown on EPS agar, and S. Typhimurium ΔbcsA ΔyihVW grown on EPS argar and 
1% Tryptone agar. This indicated that although not a direct correlation of the PyihUTSRQPO 
activity observed, the cell lysis method was adequate and most of the capsule was collected 
with the polysaccharide precipitate.  
 
 
Figure 4.1.4(a): Locating the capsule. Crude O-Antigen capsule of S. Typhimurium ΔbcsA grown on EPS agar 
detected on a Western blot. Cells: cells scraped off agar surfaces. Pellet: cell debris pellet following phenol lysis. 
Precipitate: polysaccharides precipitate following acetone treatment. Supernatant: supernatant of the polysaccharides 
precipitate containing acetone. Capsule was detected using rabbit polyclonal serum specific for S.Typhimurium O-
Antigen capsule.  
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Strain # of plates
Growth 
media
% of 
phenol PYBC mg/plate WLDC PYAC PYAC (mg/plate) FWPC (ALR)
SE bcsA 40 EPS 1% 49.1mg 1.23 - - -
ST bcsA 40 EPS 1% 24.8mg 0.62 - - -
SE bcsA 46 EPS 1% 50.0mg 1.09 - - -
ST bcsA 46 EPS 1% 30.0mg 0.65 - - -
SH WT 100 EPS 1% 34.0mg 0.34 - - -
SE bcsA 168 EPS 1% 35.1mg 0.21 - - -
SE bcsA 224 EPS 1% 108.3mg 0.48 - - -
SE bcsA 331 EPS 1% 183.5mg 0.55 73.7% (135.3mg) 48.2mg 0.15 mg/plate 1.2mg/mL DNR, S-20
o
C
SE bcsA 306 EPS 1% 143.0mg 0.47 82.2% (117.5mg) 25.5mg 0.08 mg/plate 8.9mg
SE bcsA 164 EPS 1% 115.0mg 0.64 - - NDY, S4
o
C
ST bcsA 165 EPS 1% 124.9mg 0.76 - - 2.8mg
ST bcsA 130 EPS 1%
ST bcsA 95 EPS 1%
ST bcsA yihVW 95 EPS 1% Few specks - - -
ST bcsA 83 EPS 1% 62.8mg 0.76 - - -
ST bcsA pBR-yihVW 83 EPS 1% 31.6mg 0.38 - - -
ST bcsA 150 EPS 1% - - -
ST bcsA 150 EPS 5% - - -
ST bcsA 150 EPS 5%
ST bcsA 150 EPS 5%
ST bcsA yihVW 25 EPS 5% 48.3mg 1.93 - - -
ST bcsA yihVW 25 1% Tryptone 5% 110.7mg 4.43 - - -
ST bcsA 25 EPS 5% 61.4mg 2.46 - - -
ST bcsA yihVW pBR-yihVW 25 EPS 5% 54.4mg 2.18 - - -
1% Tryptone
ST bcsA yihVW 100 1% Glucose 10% 270.2mg 2.7 24.9% (67.2mg) 203.0mg 2.03 mg/plate FSD in 1mL dH2O
1% Galactose
ST bcsA yihVW 60 1% Tryptone 10% 55.6mg 0.93 - S4
o
C -
ST bcsA 60 1% Tryptone 10% 86.6mg 1.44 - S4
o
C -
ST bcsA yihW 60 1% Tryptone 10% 215.2mg 3.59 77% (165.7mg) 49.5mg 0.83 mg/plate FSD in 1mL dH2O
PYBC = Polysaccharide yield before chromatography DNR = does not react
WLDC = Weight loss during chromatography NDY = not done yet
PYAC = Polysaccharide yield after Chromatography S4
o
C = stored at 4
o
C
FWPC (ALR) = Final weight of purified capsule(After LPS removal) FSD = few specks dissolved
-
267.2mg 1.19 55.4mg 0.25 mg/plate 1.1mg/mL DNR, S-20
o
C
196.0mg 0.65
ST bcsA yihVW 100 1% Tryptone 10% 455.7mg
128.4mg
4.56 66.5% (303.2mg) 152.5mg FSD in 1mL dH2O1.53 mg/plate
79.2% (211.8mg)
0.43 - 88.5mg 0.30 mg/plate
 
 
Table 4.1.1: Amount of O-Antigen capsule isolated after each step in the purification process. Each column 
represents the yield of O-Antigen capsule following a purification step. Each row represents a single purification 
carried out for a given strain. Unavailable data is represented by a dash line “-”. 
 
The O-Antigen capsule of Salmonella is made up of four repeating sugars: galactose, 
rhamnose, mannose and abequose (in S. Typhimurium and S. Heidelberg) or tyvelose (in S. 
Enteritidis). In addition, the galactose residue is partially substituted with a glucose side chain 
(Figure 4.1.4(b)) (Gibson et al., 2006). One possible explanation for the discrepancy between 
100-fold increased PyihUTSRQPO expression and only 2.3 times more crude capsule production 
was that there may have been inadequate sugar precursors for the cells to synthesize capsule. To 
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determine if the addition of sugar would result in an obvious increase in capsule production, 
which would be signified by a change in colony morphology, S. Typhimurium ∆bcsA ∆yihVW 
was inoculated on to the following agar containing media: EPS, LB, 1% Tryptone, Terrific broth, 
Tryptic Soy, SOC, MacConkey, Brain-Heart Infusion, 2X YT, Selenite, and Brilliant Green, 
supplemented with 1%: glucose, galactose, rhamnose, mannose, fructose, lactose, maltose, 
cellobiose, sorbose, sucrose, arabinose, or ribose. However, there was no difference in colony 
morphology between cells grown on these different conditions. 
 
 
Figure 4.1.4(b): Sugar precursors of O-Antigen capsule. Repeat units of the sugar precursors of S. Typhimurium, 
S. Heidelberg and S. Enteritidis in making the O-Antigen capsule. In addition to Glucose, Galactose, Mannose and 
Rhamnose, S. Typhimurium and S. Heidelberg have abequose, while S. Enteritidis has Tyvelose as part of the O-
Antigen capsule. 
 
In order to have a closer look at the precursor sugars’ influence on colony morphology, 
single colonies of S. Typhimurium ∆bcsA were grown on 1% tryptone agar supplemented with 
100 ug/mL of the dye congo red and 1%: glucose, galactose, rhamnose, or mannose. In the base 
media without sugar or media supplemented with 1% rhamnose, or 1% mannose, colonies were 
shiny, raised, and red/orange in colour (Figure 4.1.4(c)). However, when grown in media 
supplemented with 1% glucose or 1% galactose, colonies were dry, flat, and maroon/brown in 
colour. Since the addition of rhamnose or mannose had no noticeable influence on the colony 
morphology, we did not work with them further. A crude capsule purification was performed on 
cells grown on 1% Tryptone agar without sugar or supplemented with 1% glucose and 1% 
galactose: referred to as “no sugar” and “sugar” conditions respectively. Western blotting of 
crude O-Antigen capsule purified from S. Typhimurium ∆bcsA ∆yihVW grown in no sugar and 
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sugar conditions revealed no noticeable difference between the capsules (Figure 4.1.4(d)). 
However, based on weight, the no sugar condition produced twice as much crude polysaccharide 
precipitate as the sugar condition. Therefore, it is concluded that the lack of O-Antigen capsule 
production by the ∆yihVW mutant cannot be attributed to a deficiency in precursor sugars. 
 
 
 
Figure 4.1.4(c): Effect of Sugar Precursors on S. Typhimurium ∆bcsA ∆yihVW colony morphology. Cells were 
grown at 28oC for 2 days on 100ug/mL Congo Red + 1% Tryptone agar with no sugar, 1% glucose, 1% galactose, 
1% rhamnose or 1% mannose. Addition of Rhamnose, mannose or no sugars produced red/orange colonies, while 
glucose and galactose produced maroon/brown colonies. Identical results were obtained for S. Typhimurium ∆bcsA 
strain. 
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Figure 4.1.4(d): Comparison of crude O-Antigen capsule grown on “sugar” and “no sugar” conditions. 
Western blots showing the presence of crude O-Antigen capsule following size exclusion chromatography, detected 
using S. Typhimurium O-Antigen capsule specific serum. Cells grown on: (A) ‘no sugar condition’ - 1% Tryptone 
agar (B) ‘sugar condition’ 1% Tryptone agar, 1% glucose, and 1% galactose. 
 
4.1.5 Capsule Staining and Microscopic Imaging 
 
To determine differences in capsule production, individual cells were stained for capsule 
and visualized under a light microscope. Three S. Typhimurium strains were analyzed: WT, 
ΔbcsA, and ΔbcsA ΔyihW, that were grown on 1% Tryptone agar for 2, 7, or 29 days. Histophilus 
somni was included as a negative control, since it is known to not produce a capsule (Sandal et 
al., 2011). Cells from each strain were stained with Maneval’s Capsule Stain, which is a negative 
stain, where the cells and the background are stained, but the capsules remained unstained. Upon 
visualization with a light microscope, the cells stained pink, background stained blue and capsule 
remained unstained appearing as a white halo (Figure 4.1.5). The cells from each strain changed 
remarkably over the course of the experiment. On day 2 small, individual pink cells could be 
seen surrounded by white halos in a blue background. H. somni, being a capsule negative strain, 
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had no white halos, but pink cells in a blue background. On day 7, many cells appeared as long 
filaments. The cells in these filaments were no longer individually surrounded by a capsule halo, 
but only had a capsule halo between two cells within the filament. There were also individual 
cells such as those seen on day 2. S. Typhimurium WT and S. Typhimurium ΔbcsA ΔyihW had 
another set of cells that were in short filaments, but with large white halos surrounding the 
filaments. By day 29, the colonies of each Salmonella strain were dry and rough, while 
microscopically cells were in very short filaments made up of few cells. Once again small 
individual cells were seen as in day 2. It was interesting to note that the majority of long 
filaments from day 7 were no longer present.  
Day 2 Day 7
Day 29 H. Sommni
 
 
Figure 4.1.5: Visualization of S. Typhimurium mutants under a light microscope. S. Typhimurium WT, S. 
Typhimurium ΔbcsA, S. Typhimurium ΔbcsA ΔyihW, and H. Somni cells stained with Maneval’s Capsule Stain and 
visualized on days 2, 7, and 29. Images represent S. Typhimurium ΔbcsA ΔyihW; identical results were observed for 
all three strains.  
 
4.1.6 X-Factor Purification 
 
Gibson et al. described a second uncharacterized acidic polysaccharide, known as X-factor 
that was purified as part of the extracellular matrix (2006). This polysaccharide was negatively 
charged and was comprised of 4 main sugars: glucose, galactose, xylose, and glucuronic acid, as 
well as 4 monosaccharides that did not match any known standards (DL Gibson; Salmonella 
Enteritidis This Aggregative Fimbriae and the Extracellular Matrix, PhD Thesis, University of 
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Victoria, 2000, 208 pages). The X-factor was presumed to elute differently than the O-Antigen 
capsule during anion exchange chromatography due to the O-Antigen capsule being nearly 
neutral in overall charge (Gibson et al., 2006). After analyzing all the peaks from the anion 
exchange column on Western blots using serum specific for S. Enteritidis X-Factor (obtained 
from Deanna Gibson, UBC-Okanagan) it was determined that the X-factor was retained on the 
column following elution of all other extracellular matrix components (including the O-Antigen 
capsule). The X-factor was found to elute at the end of the run, when the anion exchange column 
was ‘cleaned’ with 2M NaCl (Figure 4.1.6(a)). Furthermore, this X-factor material was found to 
be cross-reactive with O-Antigen capsule-specific serum (obtained from Deanna Gibson, UBC-
Okanagan).  
 
 
Figure 4.1.6(a): Detection of X-factor during anion exchange chromatography. Following anion exchange 
chromatography of the O-Antigen capsule, the column was washed with 2M NaCl, which eluted out the X-factor that 
reacted with X-factor specific serum. 
 
To isolate X-factor, end fractions from the anion exchange chromatography of S. 
Typhimurium O-Antigen capsule were further separated on size exclusion chromatography 
(Figure 4.1.6(b)-A). The resulting fractions were tested on Western blots using S. Typhimurium 
X-factor-specific serum (obtained from Deanna Gibson, UBC-Okanagan) (Figure 4.1.6(b)-B). 
As with the O-Antigen capsule, X-factor was also found on the stacking and upper resolving part 
of SDS gels. The laddering on the bottom of the blot corresponds to low-molecular weight LPS 
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bands. Serum specific for S. Typhimurium O-Antigen capsule recognized crude X-factor from S. 
Typhimurium, and serum specific for S. Typhimurium LPS recognized LPS associated with X-
factor (Figure 4.1.6(c)). However, since X-factor and O-Antigen capsule elute at different points 
during the anion exchange chromatography, it is unlikely that the capsule specific serum is 
recognizing O-Antigen capsule associated with X-factor. The most probable explanation is that 
capsule-specific serum is either recognizing LPS or being polyclonal, also has specificity to X-
factor. During endotoxin removal and subsequent purifications, X-factor fractions were treated in 
the same manner as O-Antigen capsule (discussed in 4.1 “Purifications”). 
 
Figure 4.1.6(b): The X-factor. (A) Size exclusion chromatogram for X-factor.  Fractions reacted with the X-factor 
specific serum is indicated by the dashed line. (B) Western blot of crudely purified X-factor samples following size 
exclusion chromatography detected using rabbit polyclonal immune serum specific for S. Typhimurium X-factor 
(1:1000).  
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Figure 4.1.6(c): Detection of X-factor by O-Antigen capsule and LPS specific serum. S. Typhimurium X-factor 
recognized by: (A) rabbit polyclonal serum specific for S. Typhimurium O-Antigen capsule, (B) mouse monoclonal 
serum specific for S. Typhimurium LPS [1E6] (Abcam: ab65922). The high molecular weight material corresponds 
to X-factor, while the low molecular weight material corresponds to LPS. 
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4.2 Animal Trials 
4.2.1 Immune Serum Generation 
 
O-Antigen capsule samples were analyzed on Western blots using polyclonal rabbit serum 
specific for S. Typhimurium O-Antigen capsule (Figure 4.2.1(a)). Initially, S. Enteritidis O-
Antigen capsule-specific serum was used (obtained from Deanna Gibson, UBC-Okanagan), but 
there was an insufficient amount for screening of O-Antigen capsule production. Thus, rabbits 
were immunized with purified (endotoxin removed) S. Typhimurium and S. Enteritids O-Antigen 
capsule and X-factor to generate immune serum against these antigens.  
 
 
Figure 4.2.1(a): Detection of O-Antigen capsule using specific serum. S. Typhimurium and S. Enteritidis O-
Antigen capsules detected on a Western blot using polyclonal immune serum specific for S. Typhimurium O-
Antigen capsule. 
 
After three sub-cutaneous (s.c.) immunizations, given at days 0, 21 and 42, the serum 
antibody titer for each antigen was compared against the corresponding pre-bleed titers (Figure 
4.2.1(b)). For S. Typhimurium and S. Enteritidis O-Antigen capsule and X-factor-specific serum, 
1:1000 dilutions of serum were used to achieve a good signal to noise ratio, and optimal use of 
serum. Each of the pre-bleed sera had poor reactivity against the antigens, as expected. The 
specificity of these different serums was further tested against the native antigen used for 
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immunization, along with testing for cross-reactivity between S. Typhimurium and S. Enteritidis. 
Both anti S. Typhimurium and S. Enteritidis O-Antigen capsule serum can cross recognize the 
capsule from the other serovar (Figure 4.2.1(c)). However, serum against S. Typhimurium and S. 
Enteritidis X-factor was not able to cross recognize X-factor between serovars. 
 
 
 
Figure 4.2.1(b): Antibody titers of rabbits that received O-Antigen capsule and X-factor immunizations. 
ELISA following 3rd immunization with the respective antigen. 30% Emulsigen was used as the adjuvant. Serum 
dilution 0 is direct serum without any dilutions. Graphs represent the antibody titers for the following antigens: (A) 
S. Typhimurium O-Antigen capsule at a titer of 46340, (B) S. Enteritidis O-Antigen capsule at a titer of 2046, (C) S. 
Typhimurium X-factor at a titer of 3140, and (D) S. Enteritidis X-factor at a titer of 61121. 
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Figure 4.2.1(c): O-Antigen capsule and X-factor recognition ability of its respective antiserum: (A) Rabbit 
polyclonal anti-S. Typhimurium O-Antigen capsule serum, (B) Rabbit polyclonal anti-S. Enteritidis O-Antigen 
capsule serum, (C) Rabbit polyclonal anti-S. Typhimurium X-factor serum, and (D) Rabbit polyclonal anti-S. 
Enteritidis X-factor serum. The high molecular weight material corresponds to the O-Antigen capsule, while the low 
molecular weight material corresponds to LPS. 
 
4.2.2 Dosage Trial 
 
Immunization experiments were carried out to determine the dosage of O- Antigen capsule 
required to obtain the best possible immune response in mice. Seven groups of mice (n=6) were 
immunized intramuscularly (i.m.) with different concentrations of purified S. Typhimurium O-
Antigen capsule, with and without adjuvant (Figure 4.2.2(a)). The adjuvant used was the “triple-
combo” formulation developed at VIDO-InterVac, that include polyphosphazenes as a delivery 
vehicle, CPG ODN (oligo-deoxynucleotides) to stimulate the innate and adaptive immune 
systems, and Poly I:C, a cationic host defence peptide, to activate antigen presenting cells and 
other immune cells (Kovacs-Nolan et al., 2009). The positive control group of mice received 
50ug of S. Typhimurium O-Antigen capsule with 30% Emulsigen as the adjuvant. There was no 
difference in immune response between treatment groups that received O-Antigen capsule alone 
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or in combination with the adjuvant (Figure 4.2.2(b)). In addition, the average post-immunization 
titer was the same as the pre-immunization (pre-bleed) immune response, indicating that 
immunization with O-Antigen capsule did not generate a detectable level of capsule specific 
antibody. 
 
 
 
 
Figure 4.2.2(a): Dosage Trial - Antigen used and the immunization schedule. Top figure: concentration of O-
Antigen capsule and adjuvant used to immunize mice in each treatment group (n=6). Bottom figure: the 
immunization and blood sample collection timeline. 
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Figure 4.2.2(b): Immune response in mice immunized with purified O-Antigen capsule. Each group (n=6) 
received a different concentration of O-Antigen capsule with or without adjuvant. A positive control group received 
50ug antigen with 30% Emulsigen. Murine serum dilution was at 1:50, and rabbit serum dilution was at 1:1000. This 
was a controlled, randomized, double-blinded trial. 
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4.3 Gene Expression Studies 
4.3.1 Luciferase Assays and Repressor YihW 
 
Since purification of the O-antigen capsule was a difficult, inefficient and time-consuming 
process, we wanted to determine if genetic manipulation could be used to increase the amount of 
O-Antigen capsule produced by Salmonella. The genes responsible for O-Antigen capsule 
production in Salmonella are distributed into two divergently transcribed operons: yihUTSRQPO 
and yihVW (Figure 4.3.1(a)). YihU is a putative oxidoreductase, similar to E. coli 
hydroxybutyrate dehydrogenase for alternative succinic semialdehyde metabolism (Saito et al., 
2009; NCBI-blastn 2015). YihT is a putative aldolase and is involved in glycolysis among many 
other activities (Gorman et al., 2004; BioCyc 2015; NCBI-blastn 2015). YihS is a putative 
isomerase and is involved in the interconversion of monosaccharides such as mannose, fructose, 
glucose, lyxose, and xylulose (Itoh et al., 2008; BioCyc 2015; NCBI-blastn 2015). YihR is a 
putative aldolase-1-epimerase involved in sucrose, galactose, and trehalose degradation 
(Herzberg et al., 2006; BioCyc 2015; NCBI-blastn 2015). YihQ has homology to an α-
glucosidase that hydrolyses α-glucosyl fluoride, in addition to breakdown of glycogen (Okuyama 
et al., 2004; BioCyc 2015; NCBI-blastn 2015). In Salmonella, YihQ is involved in O-Antigen 
capsule assembly (Gibson et al., 2006). YihP is a GPH family transport protein similar to E. coli 
putative permease and is involved in transport of galactosides, pentoses, hexuronides (Herzberg 
et al., 2006; NCBI-blastn 2015). YihO is also a GPH family membrane transport protein and in 
Salmonella, is involved in O-Antigen capsule translocation from inside to the outside of the cell 
(Herzberg et al., 2006; NCBI-blastn 2015; Giboson et al., 2006). In the divergent operon, YihV 
is a putative sugar kinase with an unknown regulatory role (NCBI-blastn 2015; BioCyc 2015). 
YihW is a putative glycerol-3-phosphate regulon repressor similar to E. coli putative DeoR-type 
transcriptional regulator. YihW is predicted to encode a DNA binding protein – a transcriptional 
repressor (NCBI-blastn 2015; BioCyc 2015; Gibson et al., 2006).  
To examine the influence of YihV and YihW on O-Antigen capsule biosynthesis, a 
ΔyihVW strain was constructed using the λ–red recombination system (Datsenko and Wanner 
2000). The ΔyihVW strain yielded lower amounts of crude O-Antigen capsule compared to S. 
Typhimurium ΔbcsA strain (discussed in 4.1 “Purifications”). One possibility is that YihV and 
YihW were acting as positive regulators of yihUTSRQPO operon. To analyze this further, a 
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pBR322 plasmid construct containing yihVW was generated and transformed to both S. 
Typhimurium ΔbcsA and S. Typhimurium ΔbcsA ΔyihVW strains. Chromosomal deletion and 
plasmid-based over expression of yihVW was designed to indicate the influence of YihVW on 
the expression of yihUTSRQPO operon. 
 
 
Figure 4.3.1(a): The genes responsible for O-Antigen capsule production in Salmonella. The divergent 
yihUTSRQPO operon and the yihVW operon are present in all subspecies of S. enterica. 
 
To gain information about the real time expression of yihUTSRQPO and yihVW capsule 
operons at a cellular level, the promoter (PyihUTSRQPO or PyihVW) sequences were cloned into 
a luciferase reporter vector (pCS26-Pac), designed to measure gene expression via light 
production (Bjarnason et al., 2003), PyihUTSRQPO or PyihVW was cloned in front of the 
bacterial luciferase operon (luxCDABE) from Photorhabdus luminescens. Activation of 
transcription from the inserted promoter would lead to the production of light (Figure 4.3.1(b)). 
Thus the intensity of luciferase produced was a clear indication of the promoter activity. 
Reporter strains were generated with a pCS26-Pac plasmid containing either PyihUTSRQPO or 
PyihVW.  
In all four strains tested: S. Typhimurium ΔbcsA, S. Typhimurium ΔbcsA pBR322-yihVW, 
S. Typhimurium ΔbcsA ΔyihVW, and S. Typhimurium ΔbcsA ΔyihVW pBR322-yihVW promoter 
activity of yihUTSRQPO was higher than that of yihVW under biofilm inducing conditions (i.e., 
30oC in 1% Tryptone). The highest PyihUTSRQPO activity was measured in the S. Typhimurium 
ΔbcsA ΔyihVW strain, which was 100 times higher than that of the S. Typhimurium WT or S. 
Typhimurium ΔbcsA strains (Figure 4.3.1(c)). The S. Typhimurium WT and S. Typhimurium 
ΔbcsA strains had comparable levels of PyihUTSRQPO activity. The fact that the S. 
Typhimurium ΔbcsA ΔyihVW strain had the highest PyihUTSRQPO activity indicated that 
YihVW were potential negative regulators of PyihUTSRQPO transcription. In addition, S. 
Typhimurium strains containing the pBR322-yihVW  had only basal levels of PyihUTSRQPO 
activity, indicating that over-production of YihVW decreased the promoter activity of 
yihUTSRQPO. This further supported the observation that YihV and YihW alone or together act 
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as repressors of the yihUTSRQPO operon. Thus, based on gene expression levels observed in this 
assay, S. Typhimurium ΔbcsA ΔyihVW strain was expected to produce more O-Antigen capsule.  
 
 
 
Figure 4.3.1(b): The reporter plasmid pCS26-Pac. This is a low copy number plasmid containing luxCDABE of 
Photorhabdus luminescens (Bjarnason et al., 2003). 
 
As the purification protocol involved growing cells on agar surfaces, next it was 
determined whether the gene expression observed in liquid culture in luciferase assay was also 
reflected during growth on agar. Light production by individual colonies was observed for  S. 
Typhimurium ΔbcsA, S. Typhimurium ΔbcsA pBR322-yihVW, S. Typhimurium ΔbcsA ΔyihVW, 
and S. Typhimurium ΔbcsA ΔyihVW pBR322-yihVW strains. As observed in liquid culture, the 
highest PyihUTSRQPO expression occured in the S. Typhimurium ΔbcsA ΔyihVW strain – 
approximately 100 times more PyihUTSRQPO expression as compared to S. Typhimurium 
ΔbcsA (Figure 4.3.1(d)). In contrast, the S. Typhimurium ΔbcsA pBR322-yihVW and S. 
Typhimurium ΔbcsA ΔyihVW pBR322-yihVW strains had lowered light production. Therefore, 
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when comparing among the strains, growing cells on agar or liquid had no clear difference in 
PyihUTSRQPO activity.  
 
Figure 4.3.1(c): PyihUTSRQPO activity of different S. Typhimurium strains. Promoter activity of yihUTSRQPO 
in S. Typhimurium WT, S. Typhimurium ΔbcsA, and S. Typhimirum ΔbcsA ΔyihVW strains with and without 
pBR322-yihVW construct grown at 30oC in 1% Tryptone. Statistics on Graph Pad Prism 6.0 Ordinary one-way 
ANOVA: P<0.0001. Each strain has a significant difference (****) compared to S. Typhimirum ΔbcsA ΔyihVW 
strain. 
 
During crude capsule purifications neither the yihVW deleted strain (S. Typhimirum ΔbcsA 
ΔyihVW) nor the yihVW over-expressed strain (S. Typhimurium ΔbcsA pBR322-yihVW) 
produced more capsule than the parent strain (S. Typhimurium ΔbcsA) (discussed in 4.1 
“Purifications”). Thus, it was considered that maybe YihV, being a putative sugar kinase, had a 
regulatory role in capsule production, and that deletion of yihV would adversely affect the 
amount of capsule produced. Therefore, a yihW deletion strain was generated using the λ–red 
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recombination system to determine whether YihW alone can provide repression and whether 
YihV was necessary for capsule production. Expression of PyihUTSRQPO was measured by 
luciferase assays.  
 
Figure 4.3.1(d): Bioluminescence images of PyihUTSRQPO activity of S. Typhimurium cells grown on LB 
agar. PyihUTSRQPO activity is measured by the level of luciferase production: (A) S. Typhimurium ΔbcsA, (B) 
S. Typhimurium ΔbcsA ΔyihVW, (C) S. Typhimurium ΔbcsA pBR322-yihVW, and (D) S. Typhimurium ΔbcsA 
ΔyihVW pBR322-yihVW 
 
The S. Typhimurium ∆bcsA ∆yihW strain had a slightly higher PyihUTSRQPO activity 
than S. Typhimurium ∆bcsA ∆yihVW strain, but the difference was not statistically significant 
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(Figure 4.3.1(e)). This indicated that YihW alone was acting as the repressor of yihUTSRQPO 
transcription. Deletion of yihW significantly increased PyihUTSRQPO activity, and over-
expression of yihVW from plasmids reduced PyihUTSRQPO activity to background levels. 
However, once again, this increase in promoter activity in the ∆yihW strain was not reflected in 
the capsule yield (discussed in 4.1 “Purifications”). These results suggested that YihV may not 
have an important positive regulatory role in O-Antigen capsule production. Thus further testing 
is required to determine the nature of YihV regulation on O-Antigen capsule production.  
 
Figure 4.3.1(e): Comparison of PyihUTSRQPO activity in S. Typhimurium ∆bcsA, ∆bcsA ∆yihVW and ∆bcsA 
∆yihW strains. Promoter activity of yihUTSRQPO in S. Typhimurium ∆bcsA, S. Typhimurium ∆bcsA ∆yihVW, and 
S. Typhimurium ∆bcsA ∆yihW strains in 1% Tryptone grown at 30oC. Statistics on Graph Pad Prism 6.0 Kruskal-
Wallis test: P<0.0001. S. Typhimurium ∆bcsA and S. Typhimurium ∆bcsA ∆yihVW strains significant (****); S. 
Typhimurium ∆bcsA and S. Typhimurium ∆bcsA ∆yihW strains significant (****); S. Typhimurium ∆bcsA ∆yihVW 
and S. Typhimurium ∆bcsA ∆yihW strains not significant. 
 
In order to externally control capsule production, native promoters (PyihUTSRQPO and 
PyihVW) were replaced with inducible promoters Pbad or Ptac (Pbad-yihUTSRQPO and Ptac-
yihVW or Ptac-yihUTSRQPO and Pbad-yihVW) using lambda red recombinase system (Strozen 
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et al., 2012). Thus, the addition of arabinose (Pbad) or IPTG (Ptac) to the growth medium would 
lead to the activation of one operon and repression of the other, thereby controlling the capsule 
production. However, cloning of this promoter construct was not successful. 
 
4.3.2 Effect of growth Conditions on PyihUTSRQPO Activity 
 
Different growth parameters were assessed to determine the optimal condition(s) for 
maximum expression of the yihUTSRQPO capsule operon. It was hypothesized that this 
condition would also lead to increased yield of O-Antigen capsule. First, cells were grown in 
three different media: EPS media, EPS media supplemented with 40uM of 2, 2’-dipyridyl (an 
iron chelator), and 1% Tryptone. The PyihUTSRQPO activity was measured as light production 
during growth. S. Typhimurium ΔbcsA, and S. Typhimurium ΔbcsA ΔyihVW strains both had the 
highest PyihUTSRQPO activity in 1% Tryptone, and the lowest activity in EPS media containing 
2,2’-dipyridyl (Figure 4.3.2(a)). S. Typhimurium ΔbcsA ΔyihVW strain had five times greater 
PyihUTSRQPO expression in 1% Tryptone than in EPS. Thus, growth in 1% Tryptone was 
considered a better alternative to EPS media. Most of the luciferase assays were performed with 
S. Typhimurium ΔbcsA ΔyihVW strain prior to construction of S. Typhimurium ΔbcsA ΔyihW 
strain. As the difference in PyihUTSRQPO activity between the two strains was not statistically 
significant, results from S. Typhimurium ΔbcsA ΔyihVW strain was not replaced with S. 
Typhimurium ΔbcsA ΔyihW strain 
Furthermore, yihUTSRQPO promoter activity of S. Typhimurium ∆bcsA and ∆bcsA ∆yihW 
strains grown in 1% Tryptone media supplemented with glucose, galactose, rhamnose, and/or 
mannose was tested (Figure 4.3.2(b)). For S. Typhimurium ΔbcsA ΔyihW, addition of each sugar 
alone or all four sugars combined did not cause a significant increase in PyihUTSRQPO activity, 
as compared to the base media without sugar added. However for S. Typhimurium ΔbcsA, 
addition of galactose, rhamnose and mannose significantly increased PyihUTSRQPO activity. 
Yet, this increase in PyihUTSRQPO activity was notably lower than the base level expression by 
S. Typhimurium ΔbcsA ΔyihW.  
For standard O-Antigen capsule purifications, the cells were grown at 30oC under biofilm 
inducing conditions. To determine if a change in temperature to physiological level would affect 
PyihUTSRQPO expression, luciferase assays were conducted at 30oC and 37oC and 
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PyihUTSRQPO activity was measured. Both S. Typhimurium ΔbcsA and S. Typhimurium ΔbcsA 
ΔyihW strains had higher PyihUTSRQPO expression at 30oC (Figure 4.3.2(c)). The S. 
Typhimurium ΔbcsA ΔyihW strain had 1.2 times more activity at 30oC, while S. Typhimurium 
ΔbcsA strain had 9.7 times more activity at 30oC than at 37oC. Therefore, growth at 30oC was 
optimal for PyihUTSRQPO expression. 
 
 
Figure 4.3.2(a): Effect of growth media on PyihUTSRQPO activity. Promoter activity of yihUTSRQPO when 
cells were cultured at 30oC on: EPS, EPS+2,2'-dipyridyl, or 1% Tryptone media. Statistics on Graph Pad Prism 6.0 
Kruskal-Wallis test: P=0.0107. For both S. Typhimurium ∆bcsA and ∆bcsA ∆yihVW strains, the difference between 
EPS and 1% Tryptone media is significant, but the differences between the EPS or 1% Tryptone media and 
EPS+2,2’-dipyridyl media are not significant. 
It was decided to determine whether O/N growth conditions would have an impact on 
PyihUTSRQPO expression during the standard O-Antigen capsule purification protocol, because 
cells were grown O/N in liquid media before inoculating onto agar. During this analysis, 
luciferase assays were performed under standard conditions: cells diluted in 1% Tryptone and 
incubated at 30oC (Figure 4.3.2(d)). The S. Typhimurium ΔbcsA O/N culture grown in LB and at 
37oC resulted in slightly higher PyihUTSRQPO expression than cells grown in 1% Tyrptone and 
at 30oC. For S. Typhimurium ΔbcsA ΔyihW there was no significant difference in 
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PyihUTSRQPO expression if the overnight cultures were grown in 1% Tryptone or LB. 
However, O/N cultures grown at 30oC had increased PyihUTSRQPO activity than cultures grown 
at 37oC. Based on these results, the optimal PyihUTSRQPO expression was expected by 
culturing S. Typhimurium ΔbcsA ΔyihW strain O/N in LB at 30oC. 
 
 
Figure 4.3.2(b): Effect of different sugar precursors on PyihUTSRQPO activity. The S. Typhimurium ∆bcsA 
and S. Typhimurium ΔbcsA ΔyihW strains were grown at 30oC on 1% Tryptone media with or without the addition 
of 1% sugar(s): glucose, galactose, rhamnose, mannose, or all four sugars. Statistics on Graph Pad Prism 6.0 
Kruskal-Wallis test: For S. Typhimurium ΔbcsA strain P=0.0015; the difference between No sugar and 1% mannose 
(*) and between 1% Mannose and all four sugars (**) are significant. For S. Typhimurium ΔbcsA ΔyihW strain 
P=0.0040; the difference between 1% Galactose and 1% Mannose (**) and between 1% Mannose and all four 
sugars (**) are significant.  
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Figure 4.3.2(c): Expression of PyihUTSRQPO under different growth temperatures. Comparison of 
PyihUTSRQPO expression during growth at 30oC and at 37oC in 1% Tryptone for S. Typhimurium ∆bcsA and S. 
Typhimurium ΔbcsA ΔyihW. Statistics on Graph Pad Prism 6.0 Mann-Whitney test: For S. Typhimurium ΔbcsA 
strain P<0.0001 (****); the difference between 30oC and 37oC growth conditions is significant. For S. Typhimurium 
ΔbcsA ΔyihW strain P=0.0366 (*) and the difference is not significant.  
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Figure 4.3.2(d): Effect of O/N culture conditions on PyihUTSRQPO activity. Effect of O/N culture growth 
medium and temperature on PyihUTSRQPO expression during subsequent luciferase assays carried out under 
standard conditions: 1% Tryptone at 30oC. Statistics on Graph Pad Prism 6.0 Kruskal-Wallis test. For S. 
Typhimurium ΔbcsA strain P=0.1435 (ns). For S. Typhimurium ΔbcsA ΔyihW strain P=0.0559 (ns).  
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5.0 DISCUSSION 
 
5.1 Concluding Remarks 
 
The O-Antigen capsule of Non-Typhoidal Salmonella is a ubiquitous surface 
polysaccharide that may become a promising vaccine candidate for immunization against NTS 
associated gastroenteritis. O-Antigen capsule biosynthesis is controlled by the divergently 
transcribed operons yihUTSRQPO and yihVW. For the purpose of this study, O-Antigen capsule 
was purified from S. Typhimurium ΔbcsA, S. Typhimurium ΔbcsA ΔyihVW and S. Typhimurium 
ΔbcsA ΔyihW strains. Comparison of crude polysaccharide yield between the three strains 
revealed that deletion of yihVW resulted in inability to extract any polysaccharides, but over 
expression of yihVW from plasmids in S. Typhimurium ΔbcsA only produced half as much crude 
polysaccharides compared to the S. Typhimurium ΔbcsA parent strain. However, deletion of 
ΔyihW alone resulted in 2.5x more crude polysaccharide production compared to the S. 
Typhimurium ΔbcsA strain. This indicates that in the absence of repression by YihW, more 
crude polysaccharides are produced, and the over expression of the YihVW negatively affect the 
crude polysaccharide yield. As the yihVW mutant strain was unable to produce any capsule, 
YihV, being a sugar kinase, may have a positive regulatory role in O-Antigen capsule 
production. However, more experiments are needed to determine the specific regulatory nature 
of YihV. 
A luciferase based reporter system was used to observe the PyihUTSRQPO and PyihVW 
activity of S. Typhimurium ΔbcsA, S. Typhimurium ΔbcsA pBR322-yihVW, S. Typhimurium 
ΔbcsA ΔyihVW, and S. Typhimurium ΔbcsA ΔyihVW pBR322-yihVW strains. In all conditions 
tested, PyihUTSRQPO had higher expression than PyihVW. The S. Typhimurium ΔbcsA ΔyihVW 
strain had 100 times higher PyihUTSRQPO activity compared to S. Typhimurium WT and S. 
Typhimurium ΔbcsA strains. In addition, strains containing the pBR322-yihVW plasmid had only 
basal levels of PyihUTSRQPO activity, indicating that over production of YihVW decreased the 
promoter activity of PyihUTSRQPO. Comparison of PyihUTSRQPO activity between S. 
Typhimurium ∆bcsA ∆yihVW and S. Typhimurium ∆bcsA ∆yihW strains showed that there was 
no significant difference in expression between the two strains. Thus the deletion of yihW 
significantly increased PyihUTSRQPO activity, and over expression of yihVW from plasmids 
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reduced PyihUTSRQPO expression to background levels, indicating that YihW alone acts as a 
repressor of the yihUTSRQPO operon.  
However, the lack of crude capsule production, even when the PyihUTSRQPO expression 
increased by 100 times compared to the parent strain indicates that there may be other regulatory 
mechanisms governing O-Antigen capsule production, such as (a) secondary RNA structures 
preventing translation of the yihUTSRQPO operon, (b) mRNA stability, (C) post-translational 
modifications, (d) or the cell simply cannot support large amounts of capsule production, 
especially if the O-Antigen capsule machinery takes precursor subunits from the LPS assembly 
pathway. Therefore further research, such as phosphoproteome studies, are needed to understand 
the discrepancy between promoter activity and capsule production. 
Upon assessment of the influence of growth conditions on the PyihUTSRQPO activity and 
capsule production, it was observed that S. Typhimurium ΔbcsA ΔyihVW strain grown on 1% 
Tryptone media resulted in the highest PyihUTSRQPO activity, at 5X more activity than when 
grown in EPS. Thus to increase capsule production, growth in 1% Tryptone was considered a 
better alternative to EPS media. In support of this, S. Typhimurium ΔbcsA ΔyihVW grown on 1% 
Tryptone agar produced ~2.3X more crude polysaccharide compared to growth on EPS agar.  
In addition, single colonies of S. Typhimurium ΔbcsA ΔyihVW grown on 100 ug/mL 
Congo red + 1% Tryptone agar in the presence of 1% glucose or 1% galactose produced dry, flat, 
maroon/brown colonies, while in the presence of 1% rhamnose, 1% mannose, or no additional 
sugars colonies were shiny, raised, and red/orange in colour. During capsule purification, the 
presence of 1% glucose and 1% galactose in the media reduced the amount of crude capsule 
obtained by half. However, luciferase assays showed that for S. Typhimurium ΔbcsA ΔyihW 
strain, addition of either sugar alone or combined all four sugars have no significant difference in 
PyihUTSRQPO activity compared to the No Sugar condition (1% Tryptone). Among the sugars 
tested, the highest activity was observed in 1% Mannose and lowest activity was observed in the 
presence of all four sugars. Nonetheless, there were no differences observed on the 
chromatograms or Western blots between crude polysaccharides extracted from cells grown in 
the presence or absence of sugar.  
Previously it had been shown that yihUTSRQPO operon is carbon catabolite repressed in 
Salmonella, and cAMP receptor protein (CRP) binding on two sites in the regulatory region of 
the yihUTSRQPO operon is required for its transcriptional activation (Villarreal et al., 2011). The 
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implication of this is that genes that allow the use of secondary carbon sources are repressed in 
the presence of glucose or other preferred carbon sources (Bruckner and Titgemeyer 2002; 
Gorke and Stulke 2008). In Salmonella, cAMP acts as a sensory signal responding to the 
availability of glucose, and in turn affects the expression of many catabolic pathways (Botsford 
and Harman 1992; Ullmann and Monod 1968). Villarreal et al., demonstrated that growth in the 
presence of glucose had a suppressive effect on the expression of PyihUTSRQPO compared to 
growth in glycerol (2011). This observation is supported by the notion that cAMP positively 
regulates yihUTSRQPO operon leading to CRP binding and transcriptional activation, while 
glucose in the medium supresses the expression of yihUTSRQPO operon (Villarreal et al., 2011). 
As growing cells on agar or liquid culture resulted in no clear difference in PyihUTSRQPO 
activity, capsule purification was carried out by growing cells on agar surfaces. Both S. 
Typhimurium ΔbcsA and S. Typhimurium ΔbcsA ΔyihW strains had the strongest 
PyihUTSRQPO expression when they were grown at 30oC. The S. Typhimurium ΔbcsA strain 
had 9.7X greater activity at 30oC as compared at 37oC, whereas the S. Typhimurium ΔbcsA 
ΔyihW strain had 1.2X more activity at 30oC, mainly because PyihUTSRQPO expression was 
already maximal in this strain. The culture conditions that the strains were grown in O/N, prior to 
inoculating the agar plates, did not pappear to influence subsequent growth or capsule 
production.  
The effects of the growth conditions on the colony morphology and capsule production 
were also assessed. Colony morphology, capsule staining, and microscopic imaging provided 
valuable information about the characteristics of different strains, but did not reveal any unique 
distinguishing features between the strains tested. Light microscopy at a higher magnification or 
visualization with an electron microscope would be able to provide more concrete information as 
to how deletion of specific genes affects the appearance and texture of the O-Antigen capsule. 
Silver staining and Western blots, using S. Typhimurium LPS specific serum, confirmed 
that crudely purified O-Antigen capsule was associated with endotoxin (LPS) even after anion 
exchange and size exclusion chromatography. Since a LPS-dominated immune response could 
prove problematic for furture vaccine development, Triton X-114 was used to remove LPS 
associated with the crude O-Antigen capsule. Although Triton extraction removed a significant 
proportion of LPS, it also reduce the concentration of O-Antigen capsule. Even though the final 
purified O-Antigen capsule had LPS associated with it (2.5*103 EU/ml as measured by the LAL 
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assay, Section 4.1.3 “Endotoxin Removal”), this was within the biologically safe limit to 
administer to mice (LD50 was 4.55*10
6 EU/ml - Beutler et al., 1985).  
In addition to the O-Antigen capsule, a second extracellular polysaccharide called X-factor 
was also purified and tested on Western blots. X-factor was retained in the anion exchange 
column during the elution of other extra cellular matrix components (including the O-Antigen 
capsule) and only eluted at the end when the column was ‘cleaned’ with NaCl. Furthermore, 
serum specific for S. Typhimurium O-Antigen capsule was able to recognize S. Typhimurium X-
factor, and also importantly, serum specific for S. Typhimurium X-factor was able to recognize 
S. Typhimurium O-Antigen capsule. However, in contrast to the O-Antigen capsule serum, X-
factor serum did not cross recognize between serovars, such that S. Typhimurium X-factor serum 
did not recognize S. Enteritidis X-factor and vice versa. The lack of cross reactivity in the X-
factor serum between serovars could mean the immune response is strain-specific as would be 
expected if it is generated against LPS. Therefore either the X-factor serum is primarily 
recognizing LPS specific for the given serovar or the X-factor is also strain-specific. However, 
this also indicates that O-Antigen capsule specific serum, being cross reactive, is not specific for 
LPS, or has a very low reactivity with LPS. Serum was generated by immunizing rabbits with 
purified O-Antigen capsule or X-factor from S. Enteritidis and S. Typhimurium. 
Purified O-Antigen capsule was administerd at different doses with and without adjuvant 
to mice in an effort to determine the proper dosage required to generate a robust antibody 
response. However, none of the treatment groups yielded a statistically significant immune 
response to the capsule (i.e immunization with O-Antigen capsule did not generate a detectable 
level of capsule-specific antibody). This could be due to O-Antigen capsule not being a strong 
immunogen. In addition, the antibody response could be mainly IgM driven, as would be 
expected for a pure polysaccharide antigen as the O-Antigen capsule. However, the alkaline 
phonsphatase conjugated goat anti-mouse secondary antibody was specific for both heavy and 
light chains of immunoglobulins, and thus the secondary antibody was able to recognize IgG as 
well as IgM antibodies (Thermo Scientific 2015). Therefore if O-Antigen capsule specific IgM 
was present in the murine serum this would have been detected during ELISA. 
Waite and March (2002) showed that when BALB/c mice were immunized with 
Mycoplasma mycoides subsp. mycoides small colony biotype vaccine candidates (i.e. capsular 
polysaccharide conjugated to ovalbumin and whole inactivated ultrasonically disrupted M. 
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mycoides [WID]), only mice immunized with the conjugate vaccine generated a capsule-specific 
antibody response. However, upon challenge with M. mycoides, mice immunized with the 
conjugate vaccine did not develop a protective response, while mice immunized with WID 
vaccine were completely protected and exhibited a significant reduction in the bacterial load 
despite the lack of detectable antibody production (Waite and March 2002). This indicates that 
the apparent antibody response is not necessarily a direct indication of immunity and protection.  
In another study (Svenson and Lindberg 1981) it was shown that rabbits immunized with S. 
Typhimurium O-antigen (O4 and O12) conjugated to a hapten carrier suspended in Freund’s 
complete adjuvant promptly responded with antibody titers as high as those observed after 
immunization with heat-killed bacteria. However, in mice, the same antigens generated a 50-fold 
lower response as was seen with immunizations with heat-killed bacteria. Nevertheless, 
passively transferred rabbit antibodies against the polysaccharide-hapten conjugate was able to 
protect mice against challenges of 100 times the 50% lethal dose of S. Typhimurium (Svenson 
and Lindberg 1981). It had also been shown that even in the absence of a detectable primary 
antibody response, some children were able to produce a detectable memory B cell response 
towards H. influenzae type b (McVernon et al., 2003). 
Furthermore, Waite and March showed that in contrast to mouse antisera which had high 
antibody titers but no protective antibodies, rabbit serum was able to inhibit in vitro growth of M. 
mycoides. Thus it was proposed that either the mouse antibodies to M. mycoides were not active 
in vitro or immunity to M. mycoides in mice was through cell-mediated immunity rather than 
through humoral immunity. Alternatively, it was also suggested that the mechanism of antibody-
mediated protection may differ between the antibodies of rabbits and mice (Waite and March 
2002). These observations can be applied to explain the lack of antibody production by mice, but 
not rabbits, towards the O-Antigen capsule. In addition to the possibility of O-Antigen capsule 
being a poor immunogen, rabbits and mice may respond differently towards polysaccharide 
antigens, specifically the O-Antigen capsule. 
 
5.2 Future Directions 
 
It would be valuable to consider different LPS extraction methods, such that it will be 
easier to purify more O-Antigen capsule with less LPS contamination. In addition, deletion of 
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specific LPS biosynthesis genes or mutation of genes coding for proteins involved in LPS export 
pathway could potentially positively influence the yield of the O-Antigen capsule. The impact of 
the absence of LPS on Salmonella growth has to be investigated along with whether the LPS 
export pathway is also involved in O-Antigen capsule export to the cell surface. 
To better understand the discrepancy between the increased yihUTSRQPO promoter 
activity and the lack of a corresponding increase in capsule production, a closer look at the 
stability of the mRNA molecules and quantification of the amount of each protein 
(YihUTSRQPO) produced would be valuable. This could help identifying the rate-limiting step 
in the capsule biosynthesis pathway. Another possible experiment would be to perform 
transposon-mutagenesis in the S. Typhimurium ΔbcsA ΔyihW strain to determine if disruption of 
secondary genetic factors could lead to an increase in capsule production. 
A better understanding of the antigenic epitopes of the O-Antigen capsule would serve 
valuable, such that the O-Antigen capsule can be better formulated to fully expose the antigenic 
epitopes, making it easier for the immune cells to recognize the capsule. One approach would be 
to infect mice with Salmonella and use the serum from these mice to screen NTS produced 
extracellular proteins and polysaccharides (including the O-Antigen capsule) to identify whether 
O-Antigen capsule is recognized by immune serum and also what other antigens are being 
recognized by this serum that is likely to contain antibody against these extracellular antigens of 
Salmonella. 
Going forward, it is my belief that a conjugate vaccine approach chemically coupling the 
O-Antigen capsule to flagella or outer membrane proteins from Salmonella would be the most 
promising approach for development of a NTS vaccine. If the O-Antigen capsule is found to be 
non-cross protective in vivo, then a multivalent vaccine approach, as with the pneumococcus 
PPSV23 vaccine (Shapiro et al., 1991), can be used containing capsule antigens from the most 
prevalent Salmonella serovars. 
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